Evolent Health (EVH) 10-Q 2 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-37415
Entity Registrant Name	Evolent Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0454912
Entity Address, Address Line One	800 N. Glebe Road
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Arlington
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	22203
City Area Code	571
Local Phone Number	389-6000
Title of 12(b) Security	Class A Common Stock of Evolent Health, Inc., par value $0.01 per share
Trading Symbol	EVH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		113,244,482
Entity Central Index Key	0001628908
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Year Focus	2023
Document Fiscal Period Focus	Q2

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents		$ 142,530	$ 188,200
Restricted cash and restricted investments		47,477	14,492
Accounts receivable, net	[1]	345,276	254,684
Prepaid expenses and other current assets	[1]	41,416	20,678
Total current assets		576,699	478,054
Restricted cash and restricted investments		17,592	12,466
Investments in equity method investees		4,254	4,475
Property and equipment, net		83,524	87,874
Right-of-use assets - operating		27,472	49,027
Prepaid expenses and other noncurrent assets	[1]	3,163	2,378
Contract cost assets		14,648	17,461
Intangible assets, net		801,923	442,784
Goodwill		1,117,556	722,774
Total assets		2,646,831	1,817,293
Current liabilities:
Accounts payable	[1]	76,953	57,174
Accrued liabilities	[1]	166,676	111,198
Operating lease liability - current		6,218	7,122
Accrued compensation and employee benefits		38,290	52,460
Deferred revenue		6,950	5,758
Reserve for claims and performance - based arrangements	[1]	245,811	199,730
Total current liabilities		540,898	433,442
Long-term debt, net		633,013	412,986
Other long-term liabilities		4,273	4,744
Tax receivable agreement liability		112,134	45,950
Operating lease liabilities - noncurrent		56,576	56,010
Deferred tax liabilities, net		33,889	4,744
Total liabilities		1,380,783	957,876
Commitments and Contingencies (See Note 10)
Mezzanine Equity
Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 175,000 and 0 shares issued, respectively		172,829	0
Shareholders' Equity
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 113,082,503 and 101,500,558 shares issued, respectively		1,131	1,015
Additional paid-in-capital		1,774,784	1,486,857
Accumulated other comprehensive loss		(1,114)	(1,178)
Retained earnings (accumulated deficit)		(660,459)	(606,154)
Treasury stock, at cost; 1,537,582 shares issued, respectively		(21,123)	(21,123)
Total shareholders' equity		1,093,219	859,417
Total liabilities, mezzanine equity and shareholders' equity		$ 2,646,831	$ 1,817,293
[1]See Note 18 for amounts attributable to related parties included in these line items.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Mezzanine Equity
Preferred class A common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred class A common stock, shares authorized	50,000,000	50,000,000
Preferred class A common stock, shares issued	175,000	0
Shareholders' Equity
Class A common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Class A common stock, shares authorized	750,000,000	750,000,000
Class A common stock, shares issued	113,082,503	101,500,558
Treasury stock, shares issued	1,537,582	1,537,582

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue	[1]	$ 469,136	$ 319,939	$ 896,826	$ 616,996
Expenses
Cost of revenue	[1]	351,938	249,705	662,413	469,444
Selling, general and administrative expenses	[1]	90,389	58,955	180,115	117,887
Depreciation and amortization expenses		32,134	15,112	61,409	30,218
Right-of-use assets impairment		24,065	0	24,065	0
Change in fair value of contingent consideration		(7,822)	800	747	6,878
Total operating expenses		490,704	324,572	928,749	624,427
Operating loss		(21,568)	(4,633)	(31,923)	(7,431)
Interest income		604	223	1,664	340
Interest expense		(14,458)	(2,148)	(27,353)	(4,389)
Gain from equity method investees		155	1,952	578	2,548
Change in tax receivable agreement liability		0	0	(66,184)	0
Other income (expense), net		(26)	297	(246)	475
Loss before income taxes		(35,293)	(4,309)	(123,464)	(8,457)
Provision for (benefit from) income taxes		(970)	(184)	(69,159)	1,018
Loss from continuing operations		(34,323)	(4,125)	(54,305)	(9,475)
Loss from discontinued operations, net of tax	[2]	0	(463)	0	(463)
Loss before preferred dividends and accretion of Series A Preferred Stock		(34,323)	(4,588)	(54,305)	(9,938)
Dividends and accretion of Series A Preferred Stock		(7,088)	0	(13,364)	0
Net loss attributable to common shareholders of Evolent Health, Inc - Basic		(41,411)	(4,588)	(67,669)	(9,938)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted		$ (41,411)	$ (4,588)	$ (67,669)	$ (9,938)
Basic and diluted:
Continuing operations, basic (in dollars per share)		$ (0.37)	$ (0.05)	$ (0.62)	$ (0.11)
Continuing operations, diluted (in dollars per share)		(0.37)	(0.05)	(0.62)	(0.11)
Discontinued operations, basic (in dollars per share)		0	0	0	0
Discontinued operations, diluted (in dollars per share)		0	0	0	0
Basic (in dollars per share)		(0.37)	(0.05)	(0.62)	(0.11)
Diluted (in dollars per share)		$ (0.37)	$ (0.05)	$ (0.62)	$ (0.11)
Weighted-average common shares outstanding
Basic (in shares)		111,278	90,071	109,540	89,792
Diluted (in shares)		111,278	90,071	109,540	89,792
Comprehensive loss
Net loss attributable to common shareholders of Evolent Health, Inc.		$ (41,411)	$ (4,588)	$ (67,669)	$ (9,938)
Other comprehensive loss, net of taxes, related to:
Foreign currency translation adjustment		8	(288)	64	(420)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.		$ (41,403)	$ (4,876)	$ (67,605)	$ (10,358)
[1]See Note 18 for amounts attributable to unconsolidated related parties included in these line items.[2]Includes $(0.5) million loss on disposal for the three and six months ended June 30, 2022.

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Income Statement [Abstract]
Loss on disposal of discontinued operations	$ (0.5)	$ (0.5)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Performance-Based Restricted Stock Units (PSUs)	Leveraged Stock Units (LSUs)	Cumulative-effect adjustment from adoption of ASC 2020-06	Class A Common Stock	Class A Common Stock Performance-Based Restricted Stock Units (PSUs)	Class A Common Stock Leveraged Stock Units (LSUs)	Additional Paid-In Capital	Additional Paid-In Capital Performance-Based Restricted Stock Units (PSUs)	Additional Paid-In Capital Leveraged Stock Units (LSUs)	Additional Paid-In Capital Cumulative-effect adjustment from adoption of ASC 2020-06	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit) Cumulative-effect adjustment from adoption of ASC 2020-06	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021					90,759,000
Beginning balance at Dec. 31, 2021	$ 693,633			$ (66,383)	$ 908			$ 1,340,989			$ (106,172)	$ (362)	$ (626,779)	$ 39,789	$ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	12,358							12,358
Exercise of stock options (in shares)					37,000
Exercise of stock options	309							309
Restricted stock units vested, net of shares withheld for taxes (in shares)					403,000
Restricted stock units vested, net of shares withheld for taxes	(5,239)				$ 4			(5,243)
Stock units vested, net of shares withheld for taxes (in shares)					458,000
Stock units vested, net of shares withheld for taxes	(11,232)				$ 4			(11,236)
Foreign currency translation adjustment	(420)											(420)
Net loss attributable to common shareholders of Evolent Health, Inc.	(9,938)												(9,938)
Ending balance (in shares) at Jun. 30, 2022					91,657,000
Ending balance at Jun. 30, 2022	613,088				$ 916			1,231,005				(782)	(596,928)		(21,123)
Beginning balance (in shares) at Mar. 31, 2022					91,588,000
Beginning balance at Mar. 31, 2022	611,209				$ 916			1,224,250				(494)	(592,340)		(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	7,011							7,011
Restricted stock units vested, net of shares withheld for taxes (in shares)					69,000
Restricted stock units vested, net of shares withheld for taxes	(256)							(256)
Foreign currency translation adjustment	(288)											(288)
Net loss attributable to common shareholders of Evolent Health, Inc.	(4,588)												(4,588)
Ending balance (in shares) at Jun. 30, 2022					91,657,000
Ending balance at Jun. 30, 2022	$ 613,088				$ 916			1,231,005				(782)	(596,928)		(21,123)
Beginning balance (in shares) at Dec. 31, 2022	0
Beginning balance at Dec. 31, 2022	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of series A preferred stock, net of issuance costs (in shares)	175,000
Issuance of series A preferred stock, net of issuance costs	$ 168,000
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 4,829
Ending balance (in shares) at Jun. 30, 2023	175,000
Ending balance at Jun. 30, 2023	$ 172,829
Beginning balance (in shares) at Dec. 31, 2022					101,501,000
Beginning balance at Dec. 31, 2022	859,417				$ 1,015			1,486,857				(1,178)	(606,154)		(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	19,676							19,676
Exercise of stock options (in shares)					776,000
Exercise of stock options	4,654				$ 8			4,646
Restricted stock units vested, net of shares withheld for taxes (in shares)					492,000
Restricted stock units vested, net of shares withheld for taxes	(8,770)				$ 4			(8,774)
Stock units vested, net of shares withheld for taxes (in shares)						202,000	760,000
Stock units vested, net of shares withheld for taxes		$ (3,975)	$ 0			$ 2	$ 8		$ (3,977)	$ (8)
Shares issued for acquisition (in shares)					8,475,000
Shares issued for acquisition	261,271				$ 85			261,186
Class A common stock issued for payment of earn-outs (in shares)					877,000
Class A common stock issued for payment of earn-outs	28,551				$ 9			28,542
Foreign currency translation adjustment	64											64
Net loss attributable to common shareholders of Evolent Health, Inc.	(67,669)							(13,364)					(54,305)
Ending balance (in shares) at Jun. 30, 2023					113,083,000
Ending balance at Jun. 30, 2023	$ 1,093,219				$ 1,131			1,774,784				(1,114)	(660,459)		(21,123)
Beginning balance (in shares) at Mar. 31, 2023	175,000
Beginning balance at Mar. 31, 2023	$ 170,625
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 2,204
Ending balance (in shares) at Jun. 30, 2023	175,000
Ending balance at Jun. 30, 2023	$ 172,829
Beginning balance (in shares) at Mar. 31, 2023					112,552,000
Beginning balance at Mar. 31, 2023	1,121,743				$ 1,125			1,768,999				(1,122)	(626,136)		(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	8,966							8,966
Exercise of stock options (in shares)					446,000
Exercise of stock options	3,073				$ 5			3,068
Restricted stock units vested, net of shares withheld for taxes (in shares)					58,000
Restricted stock units vested, net of shares withheld for taxes	(138)							(138)
Class A common stock issued for payment of earn-outs (in shares)					27,000
Class A common stock issued for payment of earn-outs	978				$ 1			977
Foreign currency translation adjustment	8											8
Net loss attributable to common shareholders of Evolent Health, Inc.	(41,411)							(7,088)					(34,323)
Ending balance (in shares) at Jun. 30, 2023					113,083,000
Ending balance at Jun. 30, 2023	$ 1,093,219				$ 1,131			$ 1,774,784				$ (1,114)	$ (660,459)		$ (21,123)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows Used In Operating Activities
Net loss before dividends declared and accretion of Series A preferred stock	$ (54,305)	$ (9,938)
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:
Change in fair value of contingent consideration	747	6,878
Loss on discontinued operations	0	463
Gain from equity method investees	(578)	(2,548)
Depreciation and amortization expenses	61,409	30,218
Stock-based compensation expense	19,676	12,358
Deferred tax provision (benefit)	(71,019)	472
Amortization of contract cost assets	5,672	13,186
Amortization of deferred financing costs	1,915	1,079
Right-of-use asset impairment	24,065	0
Change in tax receivable agreement liability	66,184	0
Right-of-use operating assets	1,147	(669)
Operating lease liabilities	(338)	179
Other current operating cash outflows, net	20	692
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net and contract assets	(63,137)	13,042
Prepaid expenses and other current and non-current assets	(21,142)	(8,453)
Contract cost assets	(2,859)	(3,284)
Accounts payable	(12,732)	(823)
Accrued liabilities	11,944	(24,826)
Accrued compensation and employee benefits	(20,643)	(22,379)
Deferred revenue	1,050	(3,233)
Reserve for claims and performance-based arrangements	46,081	(45,334)
Other long-term liabilities	(477)	(858)
Net cash and restricted cash used in operating activities	(7,320)	(43,778)
Cash Flows Provided by (Used In) Investing Activities
Cash paid for asset acquisitions and business combinations	(388,246)	(9,070)
Proceeds from transfer of membership and release of Passport escrow	0	22,969
Return of equity method investments	799	4,175
Investments in internal-use software and purchases of property and equipment	(15,900)	(17,744)
Net cash and restricted cash provided by (used in) investing activities	(403,347)	330
Cash Flows Provided by (Used In) Financing Activities
Changes in working capital balances related to claims processing on behalf of partners	33,122	360
Proceeds from stock option exercises	4,654	309
Proceeds from issuance of long-term debt, net of offering costs	256,063	0
Repayment of long-term debt	(37,500)	0
Distributions to Sponsors	0	(14,884)
Proceeds from issuance of preferred stock, net of offering costs	168,000	0
Payment of preferred dividends	(8,535)	0
Taxes withheld and paid for vesting of equity awards	(12,745)	(16,471)
Net cash and restricted cash provided by (used in) financing activities	403,059	(30,686)
Effect of exchange rate on cash and cash equivalents and restricted cash	49	(375)
Net decrease in cash and cash equivalents and restricted cash	(7,559)	(74,509)
Cash and cash equivalents and restricted cash as of beginning-of-period	215,158	354,942
Cash and cash equivalents and restricted cash as of end-of-period	$ 207,599	$ 280,433

Organization

Organization	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports healthcare entities to improve the quality of care delivered for people with complex conditions through proven solutions that make health care simpler and more affordable. The Company made organizational changes, including re-evaluating its reportable segments, as a result of growth in our value-based specialty care business, both organically and through acquisitions. Effective during the three months ended March 31, 2023, the Company changed its reportable segments to reflect changes in the way its chief operating decision maker evaluates the performance of its operations, develops strategy and allocates capital resources. Specifically, the Company collapsed its previous Evolent Health Services and Clinical Solutions segments into one segment. The Company's historical disclosures have been recast to be consistent with the current presentation. As of June 30, 2023, the Company had unrestricted cash and cash equivalents of $142.5 million. The Company believes it has sufficient liquidity for at least the next twelve months as of the date the financial statements were available to be issued. The Company’s headquarters is located in Arlington, Virginia. Evolent Health LLC Governance

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles	Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2022 Form 10-K. Summary of Significant Accounting Policies Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2022 Form 10-K for a complete summary of our significant accounting policies. Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets. Principles of Consolidation The interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost. Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: June 30, 2023 December 31, 2022 Collateral for letters of credit for facility leases (1) $ 2,132 $ 2,269 Collateral with financial institutions (2) 16,038 10,912 Claims processing services (3) 46,899 13,777 Total restricted cash and restricted investments $ 65,069 $ 26,958 Current restricted cash $ 47,477 $ 14,492 Total current restricted cash and restricted investments $ 47,477 $ 14,492 Non-current restricted cash $ 17,592 $ 12,466 Total non-current restricted cash and restricted investments $ 17,592 $ 12,466 ———————— (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): June 30, 2023 2022 Cash and cash equivalents $ 142,530 $ 193,070 Restricted cash and restricted investments 65,069 87,363 Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 207,599 $ 280,433 Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations. Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional discussion regarding the goodwill impairment tests conducted during 2022. Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification: Corporate trade name 2 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years As part of the organizational changes as a result of growth in our value-based specialty care business, we will sunset several corporate trade names and replace them with Evolent signifying our adoption and launch of a unified brand. As a result, we re-evaluated the useful lives of our intangible assets and accelerated amortization such that all corporate trade names will be fully amortized by December 2024. Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets. Research and Development Costs Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss). Reserves for Claims and Performance-based Arrangements Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 20 for additional discussion regarding our reserves for claims and performance-based arrangements. Right of Offset Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of both June 30, 2023 and December 31, 2022, approximately 47% of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of June 30, 2023, approximately 24% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met. Leases The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases. The Company reviews long-lived assets, which include operating lease right-of-use asset assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. If impairment indicators are present and the estimated future undiscounted cash flows are less than the carrying value of the assets, the carrying values are reduced to the estimated fair value. Fair values are determined based on quoted market values, discounted cash flows and external market data, as applicable. During the three months ended June 30, 2023, the Company decommissioned its Chicago, IL lease and wrote off the associated right-of-use asset, recognizing an impairment charge of $24.1 million in right-of-use assets impairment on the consolidated statements of operations. Refer to Note 11 for additional lease disclosures. Revenue Recognition Our revenue contracts are typically multi-year arrangements with customers to provide solutions designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation See Note 5 for further discussion of our policies related to revenue recognition. Series A Senior Convertible Preferred Shares In accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company’s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares. Refer to Note 12 - Series A Senior Convertible Preferred Shares for further discussion.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards Adoption of New Accounting Standards In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU’s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity’s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8 million, reduced additional paid-in capital by $106.2 million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1 million and $41.3 million, respectively.

Transactions

Transactions	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Transactions	Transactions Business Combinations National Imaging Associates Inc. On January 20, 2023, the Company completed its acquisition of NIA, including all of the issued and outstanding shares of capital stock of NIA as well as certain assets held by Magellan Health, Inc. (“Magellan”) and certain of its subsidiaries that were used in the Magellan Specialty Health Division. NIA is a specialty benefit management organization that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine and genetics. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. Total acquisition consideration, net of cash on hand and certain closing adjustments, was $715.7 million, based on the closing price of the Company’s Class A common stock on the NYSE on January 20, 2023. The acquisition consideration consisted of approximately $387.8 million of cash consideration (inclusive of certain post-closing adjustments), 8,474,576 shares of the Company’s Class A common stock, fair valued at $261.3 million as of January 20, 2023, and an earn-out consisting of additional consideration of up to $150.0 million payable in cash and, at the Company’s election, up to 50% in shares of the Company’s Class A common stock (the “Contingent Consideration”). As of January 20, 2023, the Contingent Consideration is fair valued at $66.6 million. See Note 17 for additional information regarding the fair value determination of the earn-out consideration. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands): Purchase consideration: Cash $ 387,823 Fair value of Class A common stock issued 261,271 Fair value of contingent consideration 66,600 Total consideration $ 715,694 Tangible assets acquired: Accounts receivable $ 28,065 Prepaid expenses and other current assets 675 Total tangible assets acquired 28,740 Identifiable intangible assets acquired: Customer relationships 345,100 Technology 50,700 Corporate trade name 8,200 Total identifiable intangible assets acquired 404,000 Liabilities assumed: Accrued liabilities 5,409 Accrued compensation and employee benefits 6,173 Deferred tax liabilities, net 100,486 Deferred revenue 142 Total liabilities assumed 112,210 Goodwill (1) 395,164 Net assets acquired $ 715,694 ———————— (1) Goodwill acquired does not include $(0.4) million of measurement period adjustments. See Note 8 for additional information. The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 15 years, 5 years, and 2 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of proprietary software that supports NIA’s core business applications and specialty business. The corporate trade name reflects the value that we believe the NIA brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $56.1 million was recorded in the consolidated statements of operations and comprehensive income (loss) for the six months ended June 30, 2023, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets. The amounts above reflect management’s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of June 30, 2023, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition. We have included the financial results of NIA in our consolidated financial statements from January 20, 2023. The consolidated statements of operations and comprehensive income (loss) include $107.4 million of revenues and $(2.8) million of net loss attributable to NIA for the six months ended June 30, 2023. Implantable Provider Group On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. Total acquisition consideration, net of cash on hand and certain closing adjustments, was $461.7 million, based on the closing price of the Company’s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $256.5 million of cash consideration, 3.7 million shares of Class A common stock, fair valued at $130.2 million as of August 1, 2022, and an earn-out of up to $87.0 million, fair valued at $75.0 million as of August 1, 2022 is payable in cash and/or shares of the Company’s Class A Common Stock, at the Company’s option. See Note 17 for additional information regarding the fair value determination of the earn-out consideration. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands): Purchase consideration: Cash $ 256,488 Fair value of Class A common stock issued 130,175 Fair value of contingent consideration 75,000 Total consideration $ 461,663 Tangible assets acquired: Accounts receivable 34,155 Prepaid expenses and other current assets 636 Other non-current assets 1,393 Total tangible assets acquired 36,184 Identifiable intangible assets acquired: Customer relationships 154,000 Technology 23,900 Corporate trade name 17,800 Total identifiable intangible assets acquired 195,700 Liabilities assumed: Accounts payable 7,997 Accrued liabilities 8,083 Accrued compensation and employee benefits 423 Deferred tax liabilities, net 48,671 Deferred revenue 321 Operating lease liabilities 1,323 Total liabilities assumed 66,818 Goodwill 296,597 Net assets acquired $ 461,663 The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8 million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets. The amounts above reflect management’s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of June 30, 2023, we had not finalized the determination of fair values allocated to the deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition. Pro forma financial information (unaudited) The following unaudited condensed pro forma information presents combined financial information as if the acquisition of NIA had been effective as of January 1, 2022, the beginning of the 2022 fiscal year. The unaudited pro forma financial information includes adjustments to historical amounts including amortization of acquired intangible assets, depreciation of acquired property and equipment, interest expense for the financing of the transaction, alignment of NIA’s revenue recognition policy, and the associated income tax effects as if NIA had been included in the Company’s results of operations. This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands). For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ — $ 386,308 $ 908,251 $ 749,135 Net loss attributable to common shareholders of Evolent Health, Inc. — (28,371) (59,268) (27,207) Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company’s interim consolidated financial statements was not material.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Our revenue contracts are typically multi-year arrangements with customers to provide solutions designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and on going services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs. Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis. Disaggregation of Revenue The following table represents Evolent’s revenue disaggregated by end-market and product type: For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Medicaid $ 209,318 $ 141,502 $ 392,352 $ 279,303 Medicare 138,700 111,392 266,369 208,492 Commercial and other 121,118 67,045 238,105 129,201 Total $ 469,136 $ 319,939 $ 896,826 $ 616,996 Performance Suite $ 276,576 $ 208,085 $ 516,449 $ 379,249 Specialty Technology and Services Suite 77,052 12,874 142,368 26,454 Administrative Services 77,754 92,357 160,821 199,216 Cases 37,754 6,623 77,188 12,077 Total $ 469,136 $ 319,939 $ 896,826 $ 616,996 Transaction Price Allocated to the Remaining Performance Obligations For contracts with a term greater than one year, we have allocated approximately $33.9 million of transaction price to performance obligations that are unsatisfied as of June 30, 2023. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 62%, 91% and 100% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected. Contract Balances Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets. Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets. The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June 30, 2023 and December 31, 2022 (in thousands): June 30, 2023 December 31, 2022 Short-term receivables (1) $ 344,781 $ 246,209 Short-term deferred revenue 6,950 5,758 Long-term deferred revenue 1,853 2,533 ———————— (1) Excludes pharmacy claims receivable and premiums receivable. Changes in deferred revenue for the six months ended June 30, 2023, are as follows (in thousands): Deferred revenue Balance as of beginning-of-period $ 8,291 Reclassification to revenue, as a result of performance obligations satisfied (4,722) Cash received in advance of satisfaction of performance obligations 5,234 Balance as of end of period $ 8,803 The amount of revenue, excluding customer discounts of $1.4 million and $2.9 million for the three and six months ended June 30, 2023, respectively, recognized from performance obligations satisfied (or partially satisfied) in a previous period was $18.0 million and $22.8 million for the three and six months ended June 30, 2023, respectively, due primarily to net gain share as well as changes in other estimates. The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $19.5 million and $46.1 million for the three and six months ended June 30, 2022, respectively. Contract Cost Assets Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June 30, 2023 and 2022, the Company had $3.0 million and $3.8 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $0.4 million and $0.7 million for the three and six months ended June 30, 2023, respectively, and $0.3 million and $1.7 million for the three and six months ended June 30, 2022, respectively. In our revenue contracts, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of June 30, 2023 and 2022, the Company had $11.6 million and $18.9 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $3.0 million and $5.0 million for the three and six months ended June 30, 2023, respectively, and $1.2 million and $11.5 million for the three and six months ended June 30, 2022, respectively. These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.

Credit Losses

Credit Losses	6 Months Ended
	Jun. 30, 2023
Credit Loss [Abstract]
Credit Losses	Credit Losses We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, current inflationary pressures on our customers’ and other third parties’ ability to pay, we did not observe notable increases in delinquencies during the three months ended June 30, 2023. Accounts Receivable from Revenue Transactions Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company’s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company’s consolidated balance sheets. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts. Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of June 30, 2023, 70% were current, 20% were past due less than 60 days, with 28% past due less than 120 days and at December 31, 2022, 67% was current, 21% was past due less than 60 days, with 29% past due less than 120 days. As of June 30, 2023 and December 31, 2022, in total we reported on the consolidated balance sheet $366.2 million and $269.1 million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of $12.9 million and $10.2 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands): For the Six Months Ended June 30, 2023 2022 Balance as of beginning of period $ (10,180) $ (3,374) NIA acquisition (240) — Provision for credit losses (4,390) 322 Charge-offs 1,898 — Balance as of end of period $ (12,912) $ (3,052)

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net The following summarizes our property and equipment (in thousands): June 30, 2023 December 31, 2022 Computer hardware $ 31,139 $ 30,092 Furniture and equipment 3,968 4,214 Internal-use software development costs 203,817 189,119 Leasehold improvements 11,214 14,926 Total property and equipment 250,138 238,351 Accumulated depreciation and amortization expenses (166,614) (150,477) Total property and equipment, net $ 83,524 $ 87,874 The Company capitalized $5.7 million and $13.8 million for the three and six months ended June 30, 2023, respectively, and $7.1 million and $13.5 million for the three and six months ended June 30, 2022, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $74.1 million and $73.7 million as of June 30, 2023 and December 31, 2022, respectively. Depreciation expense related to property and equipment was $8.2 million and $16.3 million for the three and six months ended June 30, 2023, respectively, and $7.8 million and $15.4 million for the three and six months ended June 30, 2022, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.8 million and $13.5 million for the three and six months ended June 30, 2023, respectively and $6.5 million and $13.2 million for the three and six months ended June 30, 2022, respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net Goodwill Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a goodwill impairment analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. Our annual goodwill impairment review occurs on October 31 of each fiscal year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the six months ended June 30, 2023. We will perform our annual impairment test as of October 31, 2023. 2022 Goodwill Impairment Test On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company’s future revenues from such partner, the Company elected to forego the qualitative assessment and proceeded directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management’s estimates and long-term plans and applied a discount rate based on the Company’s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management’s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. Change in Goodwill The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands): Balance as of December 31, 2022 (1) $ 722,774 Goodwill acquired (2) 395,164 Measurement period adjustment (391) Foreign currency translation 9 Balance as of June 30, 2023 $ 1,117,556 Balance as of December 31, 2021 (1) $ 426,297 Foreign currency translation (69) Balance as of June 30, 2022 $ 426,228 ———————— (1) Net of cumulative inception to date impairment of $575.5 million as of December 31, 2022 and 2021. (2) Goodwill acquired from the addition of NIA in January 2023. Intangible Assets, Net Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below: June 30, 2023 December 31, 2022 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 1.5 $ 51,965 $ 23,665 $ 28,300 12.7 $ 43,600 $ 11,726 $ 31,874 Customer relationships 14.9 810,119 115,584 694,535 15.8 465,019 92,760 372,259 Technology 3.3 162,522 88,105 74,417 2.7 111,822 80,255 31,567 Below market lease, net 0.0 1,218 1,218 — 0.3 1,218 1,151 67 Provider network contracts 0.8 18,861 14,191 4,670 1.3 18,851 11,834 7,017 Total intangible assets, net $ 1,044,685 $ 242,763 $ 801,922 $ 640,510 $ 197,726 $ 442,784 Amortization expense related to intangible assets was $24.0 million and $45.1 million for the three and six months ended June 30, 2023, respectively, and $7.3 million and $14.8 million for the three and six months ended June 30, 2022, respectively. Future estimated amortization of intangible assets (in thousands) as of June 30, 2023, is as follows: 2023 $ 46,010 2024 87,529 2025 63,641 2026 63,293 2027 60,552 Thereafter 480,897 Total future amortization of intangible assets $ 801,922 As part of the organizational changes as a result of growth in our value-based specialty care business, we will sunset several corporate trade names and replace them with Evolent signifying our adoption and launch of a unified brand. As a result, we accelerated amortization such that all corporate trade names will be fully amortized by December 2024. Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets’ carrying value. We did not identify any circumstances during the three and six months ended June 30, 2023, that would require an impairment test for our intangible assets.

Long-term Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Long-term Debt	Long-term DebtCredit Agreement On August 1, 2022 (the “IPG Closing Date”), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the “Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent, collateral agent and revolver agent (the “Existing Credit Agreement” and as modified by the Amendment (defined below), the “Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) initial term loans in an aggregate principal amount of $175.0 million (the “Initial Term Loan Facility”) and (ii) revolving credit commitments in an aggregate principal amount of $50.0 million (the “Initial Revolving Facility”), the availability of which shall be determined by reference to the lesser of $50.0 million and a borrowing base calculation. The Borrowers borrowed full amount under the Initial Term Loan Facility and the Initial Revolving Facility on the IPG Closing Date. A closing fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Initial Term Loan Facility and (b) 2.00% of the aggregate amount of the commitments in respect of the Initial Revolving Facility was paid as of the IPG Closing Date. On January 20, 2023, (“the NIA Closing Date”), the Company entered into Amendment No. 1 to the Credit Agreement (the “Amendment”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) additional revolving commitments in an aggregate principal amount equal to $25.0 million (the “Incremental Revolving Facility” and together with the Initial Revolving Facility, the Revolving Facility”), and (ii) additional term loans in an aggregate principal amount equal to $240.0 million, (the “Incremental Term Loan Facility” and together with the Initial Term Loan Facility, the “Term Loan Facility”; the Revolving Facility and the Term Loan Facility are collectively referred to herein as the “Credit Facilities”). The Borrowers borrowed the full amount under the Incremental Term Loan Facility and the Incremental Revolving Facility on the NIA Closing Date to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable in connection with the NIA acquisition on the NIA Closing Date and pay transaction fees and expenses. A closing fee of (a) 3.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 3.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date. The Credit Facilities are guaranteed by the Company and the Company’s domestic subsidiaries, subject to certain customary exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain customary exceptions. All loans under the Credit Facilities will mature on the date that is the earliest of (a) the sixth anniversary of the NIA Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied. The interest rate for the Loans is calculated, at the option of the Borrowers, (a) in the case of the Term Loan Facility, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of the Revolving Facility, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%. A closing fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Incremental Term Loan Facility and (b) 2.00% of the aggregate amount of the commitments in respect of the Incremental Revolving Facility was paid as of the NIA Closing Date. The Company recorded $12.6 million and $23.7 million in interest expense related to our Credit Agreement for the three and six months ended June 30, 2023, respectively. Amounts outstanding under the Credit Facilities may be prepaid at the option of the Company, subject to the following prepayment premium (the “Prepayment Premium”): (1) 3.00% of the principal amount so prepaid after the NIA Closing Date but prior to the first anniversary of the NIA Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the NIA Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the NIA Closing Date but prior to the third anniversary of the NIA Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the NIA Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction, in each case, subject to application of the Prepayment Premium. The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Loans. We incurred $14.4 million of debt issuance costs in connection with the Loans, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the Credit Agreement. The Company recorded $0.7 million and $1.2 million in interest expense related to the amortization of the debt discount and the issuance costs for the three and six months ended June 30, 2023, respectively. During the six months ended June 30, 2023, the Company repaid $37.5 million under the Revolving Facility. As of June 30, 2023, there is $415.0 million outstanding under the Term Loan Facility and $37.5 million outstanding under the Revolving Facility. 2024 Notes In August 2020, the Company issued $117.1 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the “2024 Notes”) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5 million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0 million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020. Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company’s Class A common stock. We recorded interest expense of $0.2 million and $0.4 million for the three and six months ended June 30, 2023, respectively and $1.0 million and $2.0 million for the three and six months ended June 30, 2022, respectively. The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company’s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. The option to settle the 2024 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1 million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7 million and $1.3 million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1 million, $1.7 million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1 million decrease in additional paid-in capital and a $1.3 million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7 million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1 million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $46.2 thousand and $0.1 million for the three and six months ended June 30, 2023, respectively and $0.2 million and $0.4 million for the three and six months ended June 30, 2022, respectively. Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8 million in aggregate principal amount of such notes for shares of the Company’s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2 million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss). 2025 Notes In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the “2025 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018, pursuant to the initial purchasers’ exercise in full of their option to purchase additional notes. Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019, at a rate equal to 1.50% per annum. The 2025 Notes will mature on October 15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. The Company recorded interest expense of $0.7 million and $1.3 million for the three and six months ended June 30, 2023 and 2022, respectively. Prior to the close of business on the business day immediately preceding April 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate. The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. The option to settle the 2025 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8 million decrease in additional paid-in capital and a $2.5 million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1 million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3 million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.3 million and $0.6 million for the three and six months ended June 30, 2023, and 2022, respectively. Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Convertible Senior Notes Carrying Value The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of June 30, 2023. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of June 30, 2023 and December 31, 2022 (in thousands): June 30, 2023 December 31, 2022 2024 Notes Carrying value $ 24,018 $ 23,925 Unamortized debt discount and issuance costs 263 356 Principal amount $ 24,281 $ 24,281 Remaining amortization period (years) 1.4 1.9 Fair value (1) $ 38,000 $ 38,000 2025 Notes Carrying value $ 169,527 $ 168,885 Unamortized debt discount and issuance costs 2,973 3,615 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 2.3 2.8 Fair value (1) $ 192,445 $ 185,546 ———————— (1) Fair values for notes are derived from available trading prices closest to the respective balance sheet date. The 2024 Notes have not been traded since December 31, 2022.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Letters of Credit As of both June 30, 2023 and December 31, 2022, the Company was party to irrevocable standby letters of credit with a bank for $18.2 million and $13.1 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $18.2 million and $13.1 million, respectively, in restricted cash and restricted investments as collateral as of June 30, 2023 and December 31, 2022, respectively. The letters of credit have current expiration dates between November 2023 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. Indemnifications The Company’s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying interim consolidated financial statements. Pre-IPO Investor Registration Rights Agreement We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016. We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and six months ended June 30, 2023, respectively. Guarantees On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (“Molina”) entered into an Asset Purchase Agreement (the “Molina APA”), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the “Molina Closing”) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (“KY DOI”) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of June 30, 2023, no amounts have been funded under this guarantee. UPMC Reseller Agreement The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company’s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company’s customers. Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the “TRA”) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. Due to the reduction in the Company’s valuation allowance primarily resulting from deferred tax liabilities established as part of the NIA acquisition, the Company has recorded the remaining TRA liability of $66.2 million for the six months ended June 30, 2023, resulting in a total TRA liability of $112.1 million as of June 30, 2023. We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. Contingencies Litigation Matters We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company’s Board was negligent in its oversight of the Company’s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D’Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (“Derivative Action”). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. On April 6, 2023, a shareholder of the Company sent a letter to the Company’s Board requesting that the Company’s Board, among other things, investigate alleged wrongdoing and commence litigation for breach of fiduciary duty against the individuals named as defendants in the Derivative Action. The Company’s Board has not arrived at a final determination of what action, if any, should be taken and cannot currently estimate the loss or the range of possible losses it may experience in connection with this request. Credit and Concentration Risk The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June 30, 2023, approximately 99.2% of our $207.6 million of cash and cash equivalents, restricted cash and restricted investments were held in either bank deposits with FDIC participating banks or overnight sweep accounts invested in money-market funds and approximately 0.8% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company has not experienced any realized losses on cash and cash equivalents to date; however, no assurances can be provided. The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable: June 30, 2023 December 31, 2022 Cook County Health and Hospitals System 35.4% 42.5% Molina Healthcare 20.2% 12.0% Bright Health Management, Inc. * 11.3% ———————— * Represents less than 10.0% of the respective balance. In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners. The following table summarizes those partners who represented at least 10.0% of our consolidated revenue: For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Cook County Health and Hospitals Systems 17.6% 24.1% 17.4% 24.0% Centene Corporation 10.3% * * * Florida Blue Medicare, Inc. 11.1% 11.7% 11.5% 11.8% Molina Healthcare 16.4% * 14.9% * Blue Cross and Blue Shield of North Carolina * 10.2% * * ———————— * Represents less than 10.0% of the respective balance

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	Leases The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company’s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. In connection with various lease agreements, the Company is required to maintain $2.1 million and $2.3 million in letters of credit as of June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company held $2.1 million and $2.3 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively. Right-of-Use Asset Impairment During the three months ended June 30, 2023, the Company decommissioned its Chicago, IL lease and wrote off the associated right-of-use asset, recognizing an impairment charge of $24.1 million in right-of-use assets impairment on the consolidated statements of operations. The following table summarizes our primary office leases as of June 30, 2023 (in thousands, other than term): Location Lease Termination Term (in years) Future Minimum Lease Commitments Letter of Credit Amount Required Arlington, VA 8.6 $ 28,960 $ 1,579 Edison, NJ 2.8 1,495 222 Makati City, Philippines 4.9 3,397 — Alpharetta, GA 2.3 1,066 — Pune, India 4.8 2,765 — Brea, CA 3.9 3,777 — The following table summarizes the components of our lease expense (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Operating lease cost $ (1,727) $ 2,231 $ 213 $ 4,505 Variable lease cost 1,565 1,171 3,121 2,497 Total lease cost $ (162) $ 3,402 $ 3,334 $ 7,002 Maturity of lease liabilities (in thousands) as of June 30, 2023, is as follows: Operating lease expense 2023 $ 4,444 2024 11,610 2025 11,285 2026 10,291 2027 10,044 Thereafter 32,161 Total lease payments 79,835 Less: Interest 17,041 Present value of lease liabilities $ 62,794 Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows: June 30, 2023 Weighted average discount rate 6.71 % Weighted average remaining lease term 7.5

Convertible Preferred Equity

Convertible Preferred Equity	6 Months Ended
	Jun. 30, 2023
Temporary Equity Disclosure [Abstract]
Convertible Preferred Equity	Convertible Preferred EquityIn connection with the NIA closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the “Securities Purchase Agreement”) pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Company’s newly created Cumulative Series A Preferred Shares, par value $0.01 (the “Series A Preferred Stock”), at a purchase price of $960.00 per share, resulting in total gross proceeds to the Company of $168.0 million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses. The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company’s Class A common stock, par value $0.01 per share and all future series of the Company’s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $1,000.00 per share. Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus 6.00%. The liquidation preference of the Series A Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company’s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis. Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $40.00 of the then-current liquidation preference per share, subject to customary anti-dilution adjustments. Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations. The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed. If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed. Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025. If the Company undergoes a Change of Control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such Change of Control. In connection with the NIA closing, the Company entered into an Investors Rights Agreement with the Purchasers named in Schedule I thereto (the “Investors Rights Agreement”). The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Investors Rights Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement. In connection with the NIA closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders named in Schedule I thereto, which granted certain registration rights to Ares in respect of the shares of the Company’s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. During the three and six months ended June 30, 2023, the Company paid dividends of $4.9 million, or $27.91 per share of Series A Preferred Stock and $8.5 million, or $48.77 per share of Series A Preferred Stock. The Company accreted $2.2 million and $4.8 million of deferred issuance costs in additional paid-in-capital on the consolidated balance sheets for the three and six months ended June 30, 2023, respectively.

Loss Per Common Share

Loss Per Common Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Loss Per Common Share	Loss Per Common Share The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Net loss attributable to common shareholders of Evolent Health, Inc. $ (41,411) $ (4,588) $ (67,669) $ (9,938) Weighted-average common shares outstanding - basic and diluted 111,278 90,071 109,540 89,792 Loss per common share Basic and diluted $ (0.37) $ (0.05) $ (0.62) $ (0.11) Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method). Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs") 1,073 1,642 1,505 1,817 Stock options 976 1,852 1,106 1,807 Series A Preferred Stock 4,375 — 4,375 — Convertible senior notes 6,188 11,582 6,188 11,582 Total 12,612 15,076 13,174 15,206

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Total compensation expense by award type and line item in our interim consolidated financial statements was as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Award Type Stock options $ 14 $ 91 $ 74 $ 253 RSUs 6,903 4,647 14,392 7,948 LSUs 77 382 361 1,157 PSUs 1,972 1,892 4,849 3,000 Total compensation expense by award type $ 8,966 $ 7,012 $ 19,676 $ 12,358 Line Item Cost of revenue $ 42 $ 1,162 $ 1,582 $ 1,962 Selling, general and administrative expenses 8,924 5,850 18,094 10,396 Total compensation expense by financial statement line item $ 8,966 $ 7,012 $ 19,676 $ 12,358 No stock-based compensation was capitalized as software development costs during the three and six months ended June 30, 2023 and 2022, respectively. Stock-based awards were granted as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 RSUs 57 63 1,053 980 PSUs 8 — 432 479

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year, adjusted for discrete items recognized during the interim period. Discrete items (e.g., significant or unusual items) are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter. An income tax provision (benefit) of $(1.0) million and $(69.2) million was recognized for the three and six months ended June 30, 2023, respectively, which resulted in effective tax rates of 2.7% and 56.0%, respectively. An income tax provision (benefit) of $(0.2) million and $1.0 million for the three and six months ended June 30, 2022, respectively, which resulted in effective tax rates of 3.9% and (11.4)%, respectively. The income tax benefit recorded during the six months ended June 30, 2023, primarily relates to the $56.1 million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the NIA acquisition accounting. The income tax expense recorded during the three and six months ended June 30, 2022, primarily related to state and foreign taxes. As of June 30, 2023, the Company had unrecognized tax benefits of $1.6 million that, if recognized, would affect the overall effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year. Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 10 above for discussion of our TRA.

Investments in Equity Method In

Investments in Equity Method Investees	6 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investments in Equity Method Investees	Investments in Equity Method Investees The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs. As of June 30, 2023 and December 31, 2022, the Company’s economic interests in its equity method investments ranged between 4% and 38%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities’ earnings and losses for each reporting period. The Company’s proportional share of the gain from these investments was approximately $0.2 million and $0.6 million for the three and six months ended June 30, 2023, respectively, and $2.0 million and $2.5 million for the three and six months ended June 30, 2022, respectively. The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $4.6 million and $9.4 million for the three and six months ended June 30, 2023, respectively, and $3.9 million and $7.5 million for the three and six months ended June 30, 2022, respectively.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets. Recurring Fair Value Measurements In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration (1) $ — $ — $ 113,300 $ 113,300 Total fair value of liabilities measured on a recurring basis $ — $ — $ 113,300 $ 113,300 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration $ — $ — $ 78,000 $ 78,000 Total fair value of liabilities measured on a recurring basis $ — $ — $ 78,000 $ 78,000 ———————— (1) Represents the fair value of earn-out consideration related to the IPG and NIA transactions as described in Note 4. The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and six months ended June 30, 2023, and 2022, respectively. In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks. The acquisitions of NIA and IPG include a provision for additional equity consideration, at the Company’s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the NIA contingent consideration is the year ending December 31, 2023, and the earnout period for IPG is the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the NIA and IPG contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration. The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Six Months Ended June 30, 2023 2022 Balance as of beginning of period $ 78,000 $ 28,700 Additions 66,600 — Settlements (32,047) — Total (gain) loss, net 747 4,700 Balance as of end of period $ 113,300 $ 33,400 The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: June 30, 2023 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 113,300 Real options approach Risk-neutral expected earnout consideration $ 113,300 Weighted average discount rate 8.50% - 13.98% December 31, 2022 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 78,000 Real options approach Risk-neutral expected earnout consideration $ 77,946 Weighted average discount rate 9.85% - 10.01% Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 9 for information regarding the fair value of the 2024 Notes and 2025 Notes.

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Parties	Related Parties The entities described below are considered related parties and the balances and/or transactions with them are reported in our interim consolidated financial statements. As discussed in Note 16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees’ earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. The Company also works with UPMC, one of its founding investors. The Company’s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down. The following table presents assets and liabilities attributable to our related parties (in thousands): June 30, 2023 December 31, 2022 Assets Accounts receivable, net $ 7,326 $ 8,787 Prepaid expenses and other current assets 43 — Liabilities Accounts payable $ — $ 27 Accrued liabilities — 192 The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three Months Ended June 30, 2023 For the Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 39,486 $ 42,810 $ 94,207 $ 74,874 Expenses Cost of revenue 32,076 36,684 79,582 63,145 Selling, general and administrative expenses 997 236 1,239 302

Repositioning and Other Changes

Repositioning and Other Changes	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Repositioning and Other Changes	Repositioning and Other Changes We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. During the second quarter of 2023, the Company implemented a broad set of repositioning initiatives designed to further align the Company’s assets and talent towards the value-based specialty care opportunity, with the intent of streamlining its operations and supporting the goal of realizing long-term sustainable earnings growth. These initiatives include making organizational changes across the business that resulted in severance, terminated benefits and related payroll taxes and dedicated employee costs associated with recent acquisitions as well as third-party professional fees. Dedicated employee costs primarily include project management and technology staff costs needed to migrate acquired businesses to Evolent’s integrated technology platform and costs related to the consolidation of brands, internal operations, strategies, processes and platforms. Dedicated employee costs are limited to employees that will have no role in ongoing operations and have no planned role at Evolent once the repositioning activities are completed. Professional services costs primarily relate to services provided by a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods. The Company anticipates total repositioning charges of approximately $25.3 million which will be recorded in selling, general and administrative expenses on the consolidated statement of operations. The repositioning program is anticipated to be substantially complete by the first half of 2024. The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2023, by major type of cost (in thousands): Incurred Total Amount Expected to be Incurred in the Repositioning Plan For the Three Months Ended June 30, 2023 For the Six Months Ended June 30, 2023 Severance and termination benefits $ 4,737 $ 4,737 $ 7,300 Dedicated employee costs 1,737 1,737 7,725 Professional services 4,787 4,787 10,300 Total $ 11,261 $ 11,261 $ 25,325

Reserves for Claims and Perform

Reserves for Claims and Performance-Based Arrangements	6 Months Ended
	Jun. 30, 2023
Insurance [Abstract]
Reserves for Claims and Performance-Based Arrangements	Reserve for Claims and Performance-Based Arrangements The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. Reserves for claims and performance-based arrangements reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products. The Company’s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. Activity in reserves for claims and performance-based arrangements was as follows (in thousands): For the Six Months Ended June 30, 2023 2022 Balance, beginning of period $ 199,730 $ 171,294 Incurred health care costs: Current year to date period 385,459 246,955 Prior year to date period (26,474) 22,438 Total claims incurred 358,985 269,393 Claims paid related to: Current year to date period (179,472) (201,508) Prior year to date period (133,432) (101,145) Total claims paid (312,904) (302,653) Other adjustments (1) — (12,074) Balance, end of period $ 245,811 $ 125,960 ———————— (1) Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The following represents supplemental cash flow information (in thousands): For the Six Months Ended June 30, 2023 2022 Supplemental Disclosure of Non-cash Investing and Financing Activities Accrued property and equipment purchases $ 24 $ 1,118 Increase/decrease to goodwill from measurement period adjustments/business combinations (391) — Class A common stock issued in connection with business combinations 261,271 — Effects of Leases Operating cash flows from operating leases 6,532 7,010 Leased assets disposed of (obtained in) exchange for operating lease liabilities 1,941 4,153

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsThe Company issued a notice of redemption to the holders of its outstanding 2024 Notes on August 2, 2023, pursuant to which it will redeem the outstanding Notes for cash at a price of 100% of the principal amount of the 2024 Notes, plus accrued and unpaid interest, if any, on October 13, 2023 (the “Redemption Date”). Prior to the Redemption Date, the holders of the 2024 Notes are entitled to convert to shares of the Company’s Class A Common Stock, par value $0.01 per share (the “Common Stock”) at a rate of 54.8667 shares per $1,000 principal amount of 2024 Notes. In the event any holder delivers a conversion notice as provided in that certain Indenture dated as of August 19, 2020 (the “Indenture”) related to the 2024 Notes, the Company intends to satisfy its conversion obligation with respect to each $1,000 principal amount of 2024 Notes tendered by Physical Settlement (as defined in the Indenture). In the event such conversion would result in a fractional share of Common Stock, an amount in lieu of the fractional share based on the Daily VWAP (as defined in the Indenture) of the Common Stock on the conversion date will be paid in cash by the Company as provided in the Indenture. As of August 2, 2023, $24.3 million aggregate principal amount of the 2024 Notes is outstanding. The Company intends to fund the aggregate redemption price using cash on hand.

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2022 Form 10-K.
Accounting Estimates and Assumptions	Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying interim consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.
Principles of Consolidation	Principles of Consolidation The interim consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.
Restricted Cash and Restricted Investments	Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: June 30, 2023 December 31, 2022 Collateral for letters of credit for facility leases (1) $ 2,132 $ 2,269 Collateral with financial institutions (2) 16,038 10,912 Claims processing services (3) 46,899 13,777 Total restricted cash and restricted investments $ 65,069 $ 26,958 Current restricted cash $ 47,477 $ 14,492 Total current restricted cash and restricted investments $ 47,477 $ 14,492 Non-current restricted cash $ 17,592 $ 12,466 Total non-current restricted cash and restricted investments $ 17,592 $ 12,466 ———————— (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): June 30, 2023 2022 Cash and cash equivalents $ 142,530 $ 193,070 Restricted cash and restricted investments 65,069 87,363 Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 207,599 $ 280,433
Business Combinations	Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final
Goodwill	Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.
Intangible Assets, Net	Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification: Corporate trade name 2 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years As part of the organizational changes as a result of growth in our value-based specialty care business, we will sunset several corporate trade names and replace them with Evolent signifying our adoption and launch of a unified brand. As a result, we re-evaluated the useful lives of our intangible assets and accelerated amortization such that all corporate trade names will be fully amortized by December 2024. Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.
Research and Development Costs	Research and Development Costs Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).
Reserves for Claims and Performance-based Arrangements	Reserves for Claims and Performance-based Arrangements Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.
Right of Offset	Right of Offset Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of both June 30, 2023 and December 31, 2022, approximately 47% of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of June 30, 2023, approximately 24% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.
Leases	Leases The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases. The Company reviews long-lived assets, which include operating lease right-of-use asset assets, for impairment when facts or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. If impairment indicators are present and the estimated future undiscounted cash flows are less than the carrying value of the assets, the carrying values are reduced to the estimated fair value. Fair values are determined based on quoted market values, discounted cash flows and external market data, as applicable. During the three months ended June 30, 2023, the Company decommissioned its Chicago, IL lease and wrote off the associated right-of-use asset, recognizing an impairment charge of $24.1 million in right-of-use assets impairment on the consolidated statements of operations.
Revenue Recognition	Revenue Recognition Our revenue contracts are typically multi-year arrangements with customers to provide solutions designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services, provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both implementation and on going services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs. Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.
Series A Senior Convertible Preferred Shares	Series A Senior Convertible Preferred SharesIn accordance with ASC 480, Distinguishing Liabilities from Equity, the shares of Series A Senior Convertible Preferred Shares are classified within temporary equity, as events outside the Company’s control triggers such shares to become redeemable. Costs associated with the issuance of redeemable preferred stock are presented as discounts to the fair value of the redeemable preferred stock and are amortized using the effective interest method, over the term of the respective series of preferred shares.
Adoption of New Accounting Standards	Adoption of New Accounting Standards In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU’s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity’s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8 million, reduced additional paid-in capital by $106.2 million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1 million and $41.3 million, respectively.
Fair Value Measurement	Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets. Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Restricted Cash And Cash Equivalents	Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: June 30, 2023 December 31, 2022 Collateral for letters of credit for facility leases (1) $ 2,132 $ 2,269 Collateral with financial institutions (2) 16,038 10,912 Claims processing services (3) 46,899 13,777 Total restricted cash and restricted investments $ 65,069 $ 26,958 Current restricted cash $ 47,477 $ 14,492 Total current restricted cash and restricted investments $ 47,477 $ 14,492 Non-current restricted cash $ 17,592 $ 12,466 Total non-current restricted cash and restricted investments $ 17,592 $ 12,466 ———————— (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.
Schedule of Cash And Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): June 30, 2023 2022 Cash and cash equivalents $ 142,530 $ 193,070 Restricted cash and restricted investments 65,069 87,363 Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 207,599 $ 280,433
Schedule of Estimated Useful Lives Intangible Assets	The following summarizes the estimated useful lives by asset classification: Corporate trade name 2 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below: June 30, 2023 December 31, 2022 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 1.5 $ 51,965 $ 23,665 $ 28,300 12.7 $ 43,600 $ 11,726 $ 31,874 Customer relationships 14.9 810,119 115,584 694,535 15.8 465,019 92,760 372,259 Technology 3.3 162,522 88,105 74,417 2.7 111,822 80,255 31,567 Below market lease, net 0.0 1,218 1,218 — 0.3 1,218 1,151 67 Provider network contracts 0.8 18,861 14,191 4,670 1.3 18,851 11,834 7,017 Total intangible assets, net $ 1,044,685 $ 242,763 $ 801,922 $ 640,510 $ 197,726 $ 442,784

Transactions (Tables)

Transactions (Tables)	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Allocation of Purchase Price	The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands): Purchase consideration: Cash $ 387,823 Fair value of Class A common stock issued 261,271 Fair value of contingent consideration 66,600 Total consideration $ 715,694 Tangible assets acquired: Accounts receivable $ 28,065 Prepaid expenses and other current assets 675 Total tangible assets acquired 28,740 Identifiable intangible assets acquired: Customer relationships 345,100 Technology 50,700 Corporate trade name 8,200 Total identifiable intangible assets acquired 404,000 Liabilities assumed: Accrued liabilities 5,409 Accrued compensation and employee benefits 6,173 Deferred tax liabilities, net 100,486 Deferred revenue 142 Total liabilities assumed 112,210 Goodwill (1) 395,164 Net assets acquired $ 715,694 ———————— (1) Goodwill acquired does not include $(0.4) million of measurement period adjustments. See Note 8 for additional information. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands): Purchase consideration: Cash $ 256,488 Fair value of Class A common stock issued 130,175 Fair value of contingent consideration 75,000 Total consideration $ 461,663 Tangible assets acquired: Accounts receivable 34,155 Prepaid expenses and other current assets 636 Other non-current assets 1,393 Total tangible assets acquired 36,184 Identifiable intangible assets acquired: Customer relationships 154,000 Technology 23,900 Corporate trade name 17,800 Total identifiable intangible assets acquired 195,700 Liabilities assumed: Accounts payable 7,997 Accrued liabilities 8,083 Accrued compensation and employee benefits 423 Deferred tax liabilities, net 48,671 Deferred revenue 321 Operating lease liabilities 1,323 Total liabilities assumed 66,818 Goodwill 296,597 Net assets acquired $ 461,663
Schedule of Net Assets Acquired	The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 20, 2023, as follows (in thousands): Purchase consideration: Cash $ 387,823 Fair value of Class A common stock issued 261,271 Fair value of contingent consideration 66,600 Total consideration $ 715,694 Tangible assets acquired: Accounts receivable $ 28,065 Prepaid expenses and other current assets 675 Total tangible assets acquired 28,740 Identifiable intangible assets acquired: Customer relationships 345,100 Technology 50,700 Corporate trade name 8,200 Total identifiable intangible assets acquired 404,000 Liabilities assumed: Accrued liabilities 5,409 Accrued compensation and employee benefits 6,173 Deferred tax liabilities, net 100,486 Deferred revenue 142 Total liabilities assumed 112,210 Goodwill (1) 395,164 Net assets acquired $ 715,694 ———————— (1) Goodwill acquired does not include $(0.4) million of measurement period adjustments. See Note 8 for additional information. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands): Purchase consideration: Cash $ 256,488 Fair value of Class A common stock issued 130,175 Fair value of contingent consideration 75,000 Total consideration $ 461,663 Tangible assets acquired: Accounts receivable 34,155 Prepaid expenses and other current assets 636 Other non-current assets 1,393 Total tangible assets acquired 36,184 Identifiable intangible assets acquired: Customer relationships 154,000 Technology 23,900 Corporate trade name 17,800 Total identifiable intangible assets acquired 195,700 Liabilities assumed: Accounts payable 7,997 Accrued liabilities 8,083 Accrued compensation and employee benefits 423 Deferred tax liabilities, net 48,671 Deferred revenue 321 Operating lease liabilities 1,323 Total liabilities assumed 66,818 Goodwill 296,597 Net assets acquired $ 461,663
Schedule of Pro Forma Adjustments	The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands). For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ — $ 386,308 $ 908,251 $ 749,135 Net loss attributable to common shareholders of Evolent Health, Inc. — (28,371) (59,268) (27,207)

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table represents Evolent’s revenue disaggregated by end-market and product type: For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Medicaid $ 209,318 $ 141,502 $ 392,352 $ 279,303 Medicare 138,700 111,392 266,369 208,492 Commercial and other 121,118 67,045 238,105 129,201 Total $ 469,136 $ 319,939 $ 896,826 $ 616,996 Performance Suite $ 276,576 $ 208,085 $ 516,449 $ 379,249 Specialty Technology and Services Suite 77,052 12,874 142,368 26,454 Administrative Services 77,754 92,357 160,821 199,216 Cases 37,754 6,623 77,188 12,077 Total $ 469,136 $ 319,939 $ 896,826 $ 616,996
Schedule of Contract with Customer, Asset and Liability	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June 30, 2023 and December 31, 2022 (in thousands): June 30, 2023 December 31, 2022 Short-term receivables (1) $ 344,781 $ 246,209 Short-term deferred revenue 6,950 5,758 Long-term deferred revenue 1,853 2,533 ———————— (1) Excludes pharmacy claims receivable and premiums receivable. Changes in deferred revenue for the six months ended June 30, 2023, are as follows (in thousands): Deferred revenue Balance as of beginning-of-period $ 8,291 Reclassification to revenue, as a result of performance obligations satisfied (4,722) Cash received in advance of satisfaction of performance obligations 5,234 Balance as of end of period $ 8,803

Credit Losses (Tables)

Credit Losses (Tables)	6 Months Ended
	Jun. 30, 2023
Credit Loss [Abstract]
Schedule of Changes in Allowance for Accounts Receivable	The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands): For the Six Months Ended June 30, 2023 2022 Balance as of beginning of period $ (10,180) $ (3,374) NIA acquisition (240) — Provision for credit losses (4,390) 322 Charge-offs 1,898 — Balance as of end of period $ (12,912) $ (3,052)

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The following summarizes our property and equipment (in thousands): June 30, 2023 December 31, 2022 Computer hardware $ 31,139 $ 30,092 Furniture and equipment 3,968 4,214 Internal-use software development costs 203,817 189,119 Leasehold improvements 11,214 14,926 Total property and equipment 250,138 238,351 Accumulated depreciation and amortization expenses (166,614) (150,477) Total property and equipment, net $ 83,524 $ 87,874

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table summarizes the changes in the carrying amount of goodwill, for the periods presented (in thousands): Balance as of December 31, 2022 (1) $ 722,774 Goodwill acquired (2) 395,164 Measurement period adjustment (391) Foreign currency translation 9 Balance as of June 30, 2023 $ 1,117,556 Balance as of December 31, 2021 (1) $ 426,297 Foreign currency translation (69) Balance as of June 30, 2022 $ 426,228 ———————— (1) Net of cumulative inception to date impairment of $575.5 million as of December 31, 2022 and 2021. (2) Goodwill acquired from the addition of NIA in January 2023.
Schedule of Intangible Assets Details	The following summarizes the estimated useful lives by asset classification: Corporate trade name 2 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below: June 30, 2023 December 31, 2022 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 1.5 $ 51,965 $ 23,665 $ 28,300 12.7 $ 43,600 $ 11,726 $ 31,874 Customer relationships 14.9 810,119 115,584 694,535 15.8 465,019 92,760 372,259 Technology 3.3 162,522 88,105 74,417 2.7 111,822 80,255 31,567 Below market lease, net 0.0 1,218 1,218 — 0.3 1,218 1,151 67 Provider network contracts 0.8 18,861 14,191 4,670 1.3 18,851 11,834 7,017 Total intangible assets, net $ 1,044,685 $ 242,763 $ 801,922 $ 640,510 $ 197,726 $ 442,784
Schedule of Future Estimated Amortization of Intangible Assets	Future estimated amortization of intangible assets (in thousands) as of June 30, 2023, is as follows: 2023 $ 46,010 2024 87,529 2025 63,641 2026 63,293 2027 60,552 Thereafter 480,897 Total future amortization of intangible assets $ 801,922

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Convertible Debt	The following table summarizes the carrying value of the long-term convertible debt as of June 30, 2023 and December 31, 2022 (in thousands): June 30, 2023 December 31, 2022 2024 Notes Carrying value $ 24,018 $ 23,925 Unamortized debt discount and issuance costs 263 356 Principal amount $ 24,281 $ 24,281 Remaining amortization period (years) 1.4 1.9 Fair value (1) $ 38,000 $ 38,000 2025 Notes Carrying value $ 169,527 $ 168,885 Unamortized debt discount and issuance costs 2,973 3,615 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 2.3 2.8 Fair value (1) $ 192,445 $ 185,546 ———————— (1) Fair values for notes are derived from available trading prices closest to the respective balance sheet date. The 2024 Notes have not been traded since December 31, 2022.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Major Customers	The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable: June 30, 2023 December 31, 2022 Cook County Health and Hospitals System 35.4% 42.5% Molina Healthcare 20.2% 12.0% Bright Health Management, Inc. * 11.3% ———————— * Represents less than 10.0% of the respective balance. The following table summarizes those partners who represented at least 10.0% of our consolidated revenue: For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Cook County Health and Hospitals Systems 17.6% 24.1% 17.4% 24.0% Centene Corporation 10.3% * * * Florida Blue Medicare, Inc. 11.1% 11.7% 11.5% 11.8% Molina Healthcare 16.4% * 14.9% * Blue Cross and Blue Shield of North Carolina * 10.2% * * ———————— * Represents less than 10.0% of the respective balance

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Primary Office Leases and Maturity of Lease Liabilities	The following table summarizes our primary office leases as of June 30, 2023 (in thousands, other than term): Location Lease Termination Term (in years) Future Minimum Lease Commitments Letter of Credit Amount Required Arlington, VA 8.6 $ 28,960 $ 1,579 Edison, NJ 2.8 1,495 222 Makati City, Philippines 4.9 3,397 — Alpharetta, GA 2.3 1,066 — Pune, India 4.8 2,765 — Brea, CA 3.9 3,777 — Maturity of lease liabilities (in thousands) as of June 30, 2023, is as follows: Operating lease expense 2023 $ 4,444 2024 11,610 2025 11,285 2026 10,291 2027 10,044 Thereafter 32,161 Total lease payments 79,835 Less: Interest 17,041 Present value of lease liabilities $ 62,794
Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms	The following table summarizes the components of our lease expense (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Operating lease cost $ (1,727) $ 2,231 $ 213 $ 4,505 Variable lease cost 1,565 1,171 3,121 2,497 Total lease cost $ (162) $ 3,402 $ 3,334 $ 7,002 Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows: June 30, 2023 Weighted average discount rate 6.71 % Weighted average remaining lease term 7.5

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Net loss attributable to common shareholders of Evolent Health, Inc. $ (41,411) $ (4,588) $ (67,669) $ (9,938) Weighted-average common shares outstanding - basic and diluted 111,278 90,071 109,540 89,792 Loss per common share Basic and diluted $ (0.37) $ (0.05) $ (0.62) $ (0.11)
Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share	Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs") 1,073 1,642 1,505 1,817 Stock options 976 1,852 1,106 1,807 Series A Preferred Stock 4,375 — 4,375 — Convertible senior notes 6,188 11,582 6,188 11,582 Total 12,612 15,076 13,174 15,206

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Total compensation expense by award type and line item in our interim consolidated financial statements was as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Award Type Stock options $ 14 $ 91 $ 74 $ 253 RSUs 6,903 4,647 14,392 7,948 LSUs 77 382 361 1,157 PSUs 1,972 1,892 4,849 3,000 Total compensation expense by award type $ 8,966 $ 7,012 $ 19,676 $ 12,358 Line Item Cost of revenue $ 42 $ 1,162 $ 1,582 $ 1,962 Selling, general and administrative expenses 8,924 5,850 18,094 10,396 Total compensation expense by financial statement line item $ 8,966 $ 7,012 $ 19,676 $ 12,358
Schedule of Share-Based Awards Granted	Stock-based awards were granted as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 RSUs 57 63 1,053 980 PSUs 8 — 432 479

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities on Recurring Basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration (1) $ — $ — $ 113,300 $ 113,300 Total fair value of liabilities measured on a recurring basis $ — $ — $ 113,300 $ 113,300 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration $ — $ — $ 78,000 $ 78,000 Total fair value of liabilities measured on a recurring basis $ — $ — $ 78,000 $ 78,000 ———————— (1) Represents the fair value of earn-out consideration related to the IPG and NIA transactions as described in Note 4.
Schedule of Changes in Contingent Consideration Measured at Fair Value	The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Six Months Ended June 30, 2023 2022 Balance as of beginning of period $ 78,000 $ 28,700 Additions 66,600 — Settlements (32,047) — Total (gain) loss, net 747 4,700 Balance as of end of period $ 113,300 $ 33,400
Schedule of Valuation Techniques and Significant Unobservable Inputs	The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: June 30, 2023 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 113,300 Real options approach Risk-neutral expected earnout consideration $ 113,300 Weighted average discount rate 8.50% - 13.98% December 31, 2022 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 78,000 Real options approach Risk-neutral expected earnout consideration $ 77,946 Weighted average discount rate 9.85% - 10.01%

Related Parties (Tables)

Related Parties (Tables)	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Schedule of Related Parties	The following table presents assets and liabilities attributable to our related parties (in thousands): June 30, 2023 December 31, 2022 Assets Accounts receivable, net $ 7,326 $ 8,787 Prepaid expenses and other current assets 43 — Liabilities Accounts payable $ — $ 27 Accrued liabilities — 192 The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three Months Ended June 30, 2023 For the Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 39,486 $ 42,810 $ 94,207 $ 74,874 Expenses Cost of revenue 32,076 36,684 79,582 63,145 Selling, general and administrative expenses 997 236 1,239 302

Repositioning and Other Chang_2

Repositioning and Other Changes (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Costs Associated with the Repositioning Plan	The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2023, by major type of cost (in thousands): Incurred Total Amount Expected to be Incurred in the Repositioning Plan For the Three Months Ended June 30, 2023 For the Six Months Ended June 30, 2023 Severance and termination benefits $ 4,737 $ 4,737 $ 7,300 Dedicated employee costs 1,737 1,737 7,725 Professional services 4,787 4,787 10,300 Total $ 11,261 $ 11,261 $ 25,325

Reserves for Claims and Perfo_2

Reserves for Claims and Performance-Based Arrangements (Tables)	6 Months Ended
	Jun. 30, 2023
Insurance [Abstract]
Schedule of Activity in Claims Reserves	Activity in reserves for claims and performance-based arrangements was as follows (in thousands): For the Six Months Ended June 30, 2023 2022 Balance, beginning of period $ 199,730 $ 171,294 Incurred health care costs: Current year to date period 385,459 246,955 Prior year to date period (26,474) 22,438 Total claims incurred 358,985 269,393 Claims paid related to: Current year to date period (179,472) (201,508) Prior year to date period (133,432) (101,145) Total claims paid (312,904) (302,653) Other adjustments (1) — (12,074) Balance, end of period $ 245,811 $ 125,960 ———————— (1) Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following represents supplemental cash flow information (in thousands): For the Six Months Ended June 30, 2023 2022 Supplemental Disclosure of Non-cash Investing and Financing Activities Accrued property and equipment purchases $ 24 $ 1,118 Increase/decrease to goodwill from measurement period adjustments/business combinations (391) — Class A common stock issued in connection with business combinations 261,271 — Effects of Leases Operating cash flows from operating leases 6,532 7,010 Leased assets disposed of (obtained in) exchange for operating lease liabilities 1,941 4,153

Organization (Details)

Organization (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) segment	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments | segment	1
Cash and cash equivalents | $	$ 142,530	$ 188,200	$ 193,070

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments	$ 65,069	$ 26,958	$ 87,363
Current restricted cash	47,477	14,492
Total current restricted cash and restricted investments	47,477	14,492
Non-current restricted cash	17,592	12,466
Total non-current restricted cash and restricted investments	17,592	12,466
Collateral for letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments	2,132	2,269
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments	16,038	10,912
Claims processing services
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments	$ 46,899	$ 13,777

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Cash Reconciliation (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 142,530	$ 188,200	$ 193,070
Restricted cash and restricted investments	65,069	26,958	87,363
Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 207,599	$ 215,158	$ 280,433	$ 354,942

Basis of Presentation, Summar_6

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)	Jun. 30, 2023
Corporate trade name | Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	2 years
Corporate trade name | Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	20 years
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	11 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	25 years
Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	5 years
Provider network contracts | Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	3 years
Provider network contracts | Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	5 years

Basis of Presentation, Summar_7

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) option_to_renew_lease	Jun. 30, 2022 USD ($)	Dec. 31, 2022
Accounting Policies [Abstract]
Accounts receivable netted against claims payable	47%		47%		47%
Accounts receivable, net eligible for net basis settlement	24%		24%
Number of leases option | option_to_renew_lease			1
Right-of-use assets impairment | $	$ 24,065	$ 0	$ 24,065	$ 0

Recently Issued Accounting St_2

Recently Issued Accounting Standards (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021	Aug. 31, 2020	Oct. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	$ 1,093,219	$ 1,121,743	$ 859,417	$ 613,088	$ 611,209		$ 693,633
2024 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net								$ 78,900
2025 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net									$ 100,700
Cumulative-effect adjustment from adoption of ASC 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity							(66,383)
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	(660,459)	(626,136)	(606,154)	(596,928)	(592,340)		(626,779)
Retained Earnings | Cumulative-effect adjustment from adoption of ASC 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity							39,789
Additional Paid-In Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	$ 1,774,784	$ 1,768,999	$ 1,486,857	$ 1,231,005	$ 1,224,250		1,340,989
Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity							$ (106,172)
Accounting Standards Update 2020-06 | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2024 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net						$ 25,100
Accounting Standards Update 2020-06 | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2025 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net						41,300
Accounting Standards Update 2020-06 | Retained Earnings | Cumulative-effect adjustment from adoption of ASC 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity						39,800
Accounting Standards Update 2020-06 | Retained Earnings | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2024 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity						(11,700)
Accounting Standards Update 2020-06 | Retained Earnings | Cumulative-effect adjustment from adoption of ASC 2020-06 | 2025 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity						28,100
Accounting Standards Update 2020-06 | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity						$ (106,200)

Transactions - Narrative (Detai

Transactions - Narrative (Details) - USD ($)				3 Months Ended		6 Months Ended		12 Months Ended
		Jan. 20, 2023	Aug. 01, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Cash						$ 388,246,000	$ 9,070,000
Discrete tax benefit				$ 970,000	$ 184,000	69,159,000	(1,018,000)
Revenue	[1]			469,136,000	319,939,000	896,826,000	616,996,000
Net loss attributable to common shareholders of Evolent Health, Inc.				$ (34,323,000)	$ (4,588,000)	(54,305,000)	$ (9,938,000)
NIA
Business Acquisition [Line Items]
Total consideration		$ 715,694,000
Cash		387,823,000
Fair value of Class A common stock issued		261,271,000
Contingent consideration arrangements (up to)		$ 150,000,000
Percentage of contingent consideration allowed to be paid in equity interest (up to)		50%
Contingent consideration		$ 66,600,000
Goodwill, expected tax deductible amount		$ 0
Discrete tax benefit						56,100,000
Revenue						107,400,000
Net loss attributable to common shareholders of Evolent Health, Inc.						$ (2,800,000)
NIA | Common Class A
Business Acquisition [Line Items]
Equity interest issued or issuable, number of shares (in shares)		8,474,576
NIA | Customer relationships
Business Acquisition [Line Items]
Estimated useful life		15 years
NIA | Technology
Business Acquisition [Line Items]
Estimated useful life		5 years
NIA | Corporate trade name
Business Acquisition [Line Items]
Estimated useful life		2 years
IPG
Business Acquisition [Line Items]
Total consideration			$ 461,663,000
Cash			$ 256,488,000
Equity interest issued or issuable, number of shares (in shares)			3,700,000
Fair value of Class A common stock issued			$ 130,175,000
Contingent consideration arrangements (up to)			87,000,000
Contingent consideration			75,000,000
Goodwill, expected tax deductible amount			$ 0
Discrete tax benefit								$ 46,800,000
Voting interests acquired			100%
IPG | Customer relationships
Business Acquisition [Line Items]
Estimated useful life			20 years
IPG | Technology
Business Acquisition [Line Items]
Estimated useful life			5 years
IPG | Corporate trade name
Business Acquisition [Line Items]
Estimated useful life			15 years
[1]See Note 18 for amounts attributable to unconsolidated related parties included in these line items.

Transactions - Allocation of Ac

Transactions - Allocation of Acquisition Cost (Details) - USD ($) $ in Thousands			5 Months Ended	6 Months Ended
	Jan. 20, 2023	Aug. 01, 2022	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Purchase consideration:
Cash				$ 388,246	$ 9,070
Liabilities assumed:
Goodwill			$ 1,117,556	1,117,556	$ 426,228	$ 722,774	$ 426,297
Measurement period adjustment				$ (391)
NIA
Purchase consideration:
Cash	$ 387,823
Fair value of Class A common stock issued	261,271
Fair value of contingent consideration	66,600
Total consideration	715,694
Tangible assets acquired:
Accounts receivable	28,065
Prepaid expenses and other current assets	675
Total tangible assets acquired	28,740
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired	404,000
Liabilities assumed:
Accrued liabilities	5,409
Accrued compensation and employee benefits	6,173
Deferred tax liabilities, net	100,486
Deferred revenue	142
Total liabilities assumed	112,210
Goodwill	395,164
Net assets acquired	715,694
Measurement period adjustment			$ (400)
NIA | Customer relationships
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired	345,100
NIA | Technology
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired	50,700
NIA | Corporate trade name
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired	$ 8,200
IPG
Purchase consideration:
Cash		$ 256,488
Fair value of Class A common stock issued		130,175
Fair value of contingent consideration		75,000
Total consideration		461,663
Tangible assets acquired:
Accounts receivable		34,155
Prepaid expenses and other current assets		636
Other non-current assets		1,393
Total tangible assets acquired		36,184
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired		195,700
Liabilities assumed:
Accounts payable		7,997
Accrued liabilities		8,083
Accrued compensation and employee benefits		423
Deferred tax liabilities, net		48,671
Deferred revenue		321
Operating lease liabilities		1,323
Total liabilities assumed		66,818
Goodwill		296,597
Net assets acquired		461,663
IPG | Customer relationships
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired		154,000
IPG | Technology
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired		23,900
IPG | Corporate trade name
Identifiable intangible assets acquired:
Total identifiable intangible assets acquired		$ 17,800

Transactions - Pro Forma Inform

Transactions - Pro Forma Information (Details) - NIA - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Acquisition [Line Items]
Revenue	$ 0	$ 386,308	$ 908,251	$ 749,135
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 0	$ (28,371)	$ (59,268)	$ (27,207)

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	[1]	$ 469,136	$ 319,939	$ 896,826	$ 616,996
Evolent Health Services Segment
Disaggregation of Revenue [Line Items]
Revenue		469,136	319,939	896,826	616,996
Evolent Health Services Segment | Performance Suite
Disaggregation of Revenue [Line Items]
Revenue		276,576	208,085	516,449	379,249
Evolent Health Services Segment | Specialty Technology and Services Suite
Disaggregation of Revenue [Line Items]
Revenue		77,052	12,874	142,368	26,454
Evolent Health Services Segment | Administrative Services
Disaggregation of Revenue [Line Items]
Revenue		77,754	92,357	160,821	199,216
Evolent Health Services Segment | Cases
Disaggregation of Revenue [Line Items]
Revenue		37,754	6,623	77,188	12,077
Evolent Health Services Segment | Medicaid
Disaggregation of Revenue [Line Items]
Revenue		209,318	141,502	392,352	279,303
Evolent Health Services Segment | Medicare
Disaggregation of Revenue [Line Items]
Revenue		138,700	111,392	266,369	208,492
Evolent Health Services Segment | Commercial and other
Disaggregation of Revenue [Line Items]
Revenue		$ 121,118	$ 67,045	$ 238,105	$ 129,201
[1]See Note 18 for amounts attributable to unconsolidated related parties included in these line items.

Revenue Recognition - Transacti

Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details) $ in Millions	Jun. 30, 2023 USD ($)
Revenue from Contract with Customer [Abstract]
Performance obligation	$ 33.9
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | December 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	62%
Remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | December 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	91%
Remaining performance obligation, expected timing of satisfaction, period	18 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | December 31, 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	100%
Remaining performance obligation, expected timing of satisfaction, period	30 months

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Short-term receivables	$ 344,781		$ 344,781		$ 246,209
Short-term deferred revenue	6,950		6,950		5,758
Long-term deferred revenue	1,853		1,853		$ 2,533
Deferred revenue
Balance as of beginning-of-period			8,291
Reclassification to revenue, as a result of performance obligations satisfied			(4,722)
Cash received in advance of satisfaction of performance obligations			5,234
Balance as of end of period	8,803		8,803
Revenue	1,400		2,900
Revenue recognized from performed obligations	$ 18,000	$ 19,500	$ 22,800	$ 46,100

Revenue Recognition - Contrac_2

Revenue Recognition - Contract Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Capitalized Contract Cost [Line Items]
Contract cost amortization			$ 5,672	$ 13,186
Amortization period	5 years		5 years
Bonuses and Commissions
Capitalized Contract Cost [Line Items]
Contract cost assets	$ 3,000	$ 3,800	$ 3,000	3,800
Contract cost amortization	400	300	700	1,700
Contract Fulfillment Costs
Capitalized Contract Cost [Line Items]
Contract cost assets	11,600	18,900	11,600	18,900
Contract cost amortization	$ 3,000	$ 1,200	$ 5,000	$ 11,500

Credit Losses - Accounts Receiv

Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, current	70%	67%
Accounts receivable, net	$ 366,200	$ 269,100
Allowance for doubtful accounts, current	$ 12,912	$ 10,180	$ 3,052	$ 3,374
Past due less than 60 days
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, past due	20%	21%
Past due less than 120 days
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, past due	28%	29%

Credit Losses - Schedule of Cha

Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance as of beginning of period	$ (10,180)	$ (3,374)
NIA acquisition	(240)	0
Provision for credit losses	(4,390)	322
Charge-offs	1,898	0
Balance as of end of period	$ (12,912)	$ (3,052)

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Property and Equipment [Line Items]
Total property and equipment	$ 250,138		$ 250,138		$ 238,351
Accumulated depreciation and amortization expenses	(166,614)		(166,614)		(150,477)
Total property and equipment, net	83,524		83,524		87,874
Net capitalized internal-use software development costs	74,100		74,100		73,700
Depreciation expense	8,200	$ 7,800	16,300	$ 15,400
Capitalized computer software, amortization	6,800	6,500	13,500	13,200
Computer hardware
Property and Equipment [Line Items]
Total property and equipment	31,139		31,139		30,092
Furniture and equipment
Property and Equipment [Line Items]
Total property and equipment	3,968		3,968		4,214
Internal-use software development costs
Property and Equipment [Line Items]
Total property and equipment	203,817		203,817		189,119
Capitalized computer software additions	5,700	$ 7,100	13,800	$ 13,500
Leasehold improvements
Property and Equipment [Line Items]
Total property and equipment	$ 11,214		$ 11,214		$ 14,926

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Impairment Testing (Details)	Oct. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Balance as of beginning of period	$ 722,774	$ 426,297
Goodwill acquired	395,164
Measurement period adjustment	(391)
Foreign currency translation	9	(69)
Balance as of end of period	$ 1,117,556	$ 426,228
Cumulative inception to date impairment			$ 575,500	$ 575,500

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,044,685		$ 1,044,685		$ 640,510
Accumulated Amortization	242,763		242,763		197,726
Total future amortization of intangible assets	801,922		801,922		$ 442,784
Amortization of intangible assets	24,000	$ 7,300	$ 45,100	$ 14,800
Corporate trade name
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			1 year 6 months		12 years 8 months 12 days
Gross Carrying Amount	51,965		$ 51,965		$ 43,600
Accumulated Amortization	23,665		23,665		11,726
Total future amortization of intangible assets	28,300		$ 28,300		$ 31,874
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			14 years 10 months 24 days		15 years 9 months 18 days
Gross Carrying Amount	810,119		$ 810,119		$ 465,019
Accumulated Amortization	115,584		115,584		92,760
Total future amortization of intangible assets	694,535		$ 694,535		$ 372,259
Technology
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			3 years 3 months 18 days		2 years 8 months 12 days
Gross Carrying Amount	162,522		$ 162,522		$ 111,822
Accumulated Amortization	88,105		88,105		80,255
Total future amortization of intangible assets	74,417		$ 74,417		$ 31,567
Below market lease, net
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			0 years		3 months 18 days
Gross Carrying Amount	1,218		$ 1,218		$ 1,218
Accumulated Amortization	1,218		1,218		1,151
Total future amortization of intangible assets	0		$ 0		$ 67
Provider network contracts
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life			9 months 18 days		1 year 3 months 18 days
Gross Carrying Amount	18,861		$ 18,861		$ 18,851
Accumulated Amortization	14,191		14,191		11,834
Total future amortization of intangible assets	$ 4,670		$ 4,670		$ 7,017

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 46,010
2024	87,529
2025	63,641
2026	63,293
2027	60,552
Thereafter	480,897
Total future amortization of intangible assets	$ 801,922	$ 442,784

Long-term Debt - 2022 Credit Ag

Long-term Debt - 2022 Credit Agreement (Details) $ in Millions			3 Months Ended		6 Months Ended
	Jan. 20, 2023 USD ($) day	Aug. 01, 2022 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2023 USD ($)
Secured Debt | 2022 Credit Facilities
Debt Instrument [Line Items]
Interest expense			$ 12.6		$ 23.7
Unamortized debt discount and issuance costs		$ 14.4
Amortization of the debt discount and the issuance costs			0.7		1.2
Secured Debt | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 240	$ 175
Closing fee percentage	3%	2%
Number of days prior to any junior debt maturity | day	91
Commitment fee percentage		2%
Amount outstanding			415		415
Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate		6%
Secured Debt | Line of Credit | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		5%
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25	$ 50
Closing fee percentage	3%	2%
Commitment fee percentage		2%
Amount outstanding			$ 37.5		$ 37.5
Revolving Credit Facility | Line of Credit | 2022 Credit Facilities
Debt Instrument [Line Items]
Repaid under the revolving credit facility				$ 37.5
Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate		4%
Revolving Credit Facility | Line of Credit | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		3%
2022 Credit Facilities | Line of Credit
Debt Instrument [Line Items]
Prepayment penalty prior to first anniversary of closing date (in percent)		3%
Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)		2%
Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)		1%
Prepayment penalty on or after third anniversary of closing date (in percent)		0%

Long-term Debt - 2024 Notes (De

Long-term Debt - 2024 Notes (Details)			1 Months Ended		3 Months Ended		6 Months Ended
	Aug. 18, 2022 shares	Aug. 11, 2022 USD ($)	Aug. 31, 2022 USD ($)	Aug. 31, 2020 USD ($) shares $ / shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jan. 01, 2022 USD ($)	Dec. 31, 2021 USD ($)
Debt Instrument [Line Items]
Stockholders' equity					$ 1,093,219,000	$ 613,088,000	$ 1,093,219,000	$ 613,088,000	$ 1,121,743,000	$ 859,417,000	$ 611,209,000		$ 693,633,000
Amortization of deferred financing costs							1,915,000	1,079,000
Cumulative-effect adjustment from adoption of ASC 2020-06
Debt Instrument [Line Items]
Stockholders' equity													(66,383,000)
Class A Common Stock
Debt Instrument [Line Items]
Stockholders' equity					1,131,000	916,000	1,131,000	916,000	1,125,000	1,015,000	916,000		908,000
Additional Paid-In Capital
Debt Instrument [Line Items]
Stockholders' equity					1,774,784,000	1,231,005,000	1,774,784,000	1,231,005,000	1,768,999,000	1,486,857,000	1,224,250,000		1,340,989,000
Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06
Debt Instrument [Line Items]
Stockholders' equity													(106,172,000)
Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity												$ (106,200,000)
Retained Earnings (Accumulated Deficit)
Debt Instrument [Line Items]
Stockholders' equity					(660,459,000)	(596,928,000)	(660,459,000)	(596,928,000)	$ (626,136,000)	(606,154,000)	$ (592,340,000)		(626,779,000)
Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06
Debt Instrument [Line Items]
Stockholders' equity													$ 39,789,000
Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity												39,800,000
Senior Notes
Debt Instrument [Line Items]
Payments of debt issuance costs				$ 2,500,000
2024 Notes | Senior Notes
Debt Instrument [Line Items]
Face amount				$ 117,100,000	24,281,000		24,281,000			$ 24,281,000
Interest rate				3.50%
Debt conversion, converted instrument, amount				$ 84,200,000
Debt issuance costs				$ 3,000,000
Interest expense					200,000	1,000,000	400,000	2,000,000
Conversion price (in dollars per share) | $ / shares				$ 18.23
Initial conversion amount (in shares) | shares				6,400,000
Long-term debt, net				$ 78,900,000
Debt issuance costs, net, debt component				$ 1,700,000
Amortization of deferred financing costs					$ 46,200	$ 200,000	$ 100,000	$ 400,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount				100%
Repurchase covenant, sale price as a percentage of conversion price				130%
Repurchase covenant, trading days, minimum				20 days
Consecutive trading days, minimum				30 days
Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price				100%
Loss on extinguishment/repayment of debt, net			$ 10,200,000
2024 Notes | Senior Notes | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Long-term debt, net												25,100,000
2024 Notes | Senior Notes | Class A Common Stock
Debt Instrument [Line Items]
Debt issuance costs				$ 1,300,000
Proceeds from issuance of debt				$ 38,100,000
2024 Notes | Senior Notes | Class A Common Stock | Common Class A
Debt Instrument [Line Items]
Initial conversion rate				0.0548667
2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt
Debt Instrument [Line Items]
Stockholders' equity												(38,100,000)
2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Deferred Financing Fees
Debt Instrument [Line Items]
Stockholders' equity												1,300,000
2024 Notes | Senior Notes | Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity												$ (11,700,000)
2021 Notes | Senior Notes
Debt Instrument [Line Items]
Debt conversion, original debt, amount		$ 92,800,000		$ 84,200,000
Debt conversion issued (in shares) | shares	5,394,165
New Notes | Senior Notes
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount				$ 32,800,000

Long-term Debt - 2025 Notes (De

Long-term Debt - 2025 Notes (Details) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Oct. 31, 2018 USD ($) shares $ / shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jan. 01, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 24, 2018 USD ($)	Oct. 22, 2018 USD ($)
Debt Instrument [Line Items]
Stockholders' equity		$ 1,093,219,000	$ 613,088,000	$ 1,093,219,000	$ 613,088,000		$ 1,121,743,000	$ 859,417,000	$ 611,209,000		$ 693,633,000
Amortization of deferred financing costs				1,915,000	1,079,000
Cumulative-effect adjustment from adoption of ASC 2020-06
Debt Instrument [Line Items]
Stockholders' equity											(66,383,000)
Class A Common Stock
Debt Instrument [Line Items]
Stockholders' equity		1,131,000	916,000	1,131,000	916,000		1,125,000	1,015,000	916,000		908,000
Additional Paid-In Capital
Debt Instrument [Line Items]
Stockholders' equity		1,774,784,000	1,231,005,000	1,774,784,000	1,231,005,000		1,768,999,000	1,486,857,000	1,224,250,000		1,340,989,000
Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06
Debt Instrument [Line Items]
Stockholders' equity											(106,172,000)
Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity										$ (106,200,000)
Retained Earnings (Accumulated Deficit)
Debt Instrument [Line Items]
Stockholders' equity		(660,459,000)	(596,928,000)	(660,459,000)	(596,928,000)		$ (626,136,000)	(606,154,000)	$ (592,340,000)		(626,779,000)
Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06
Debt Instrument [Line Items]
Stockholders' equity											$ 39,789,000
Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity										39,800,000
2025 Notes
Debt Instrument [Line Items]
Debt issuance costs	$ 5,900,000
Senior Notes | 2025 Notes
Debt Instrument [Line Items]
Face amount	$ 172,500,000	172,500,000		172,500,000				$ 172,500,000				$ 22,500,000	$ 150,000,000
Interest rate	1.50%
Proceeds from issuance of debt	$ 166,600,000
Debt issuance costs	$ 3,400,000
Interest expense		700,000	700,000	1,300,000	$ 1,300,000
Conversion price (in dollars per share) | $ / shares	$ 33.43
Initial conversion amount (in shares) | shares	5.2
Carrying amount	$ 100,700,000
Amortization of deferred financing costs		$ 300,000	$ 300,000	$ 600,000		$ 600,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100%
Repurchase covenant, sale price as a percentage of conversion price (at least)	130%
Repurchase covenant, trading days, minimum	20 days
Consecutive trading days, minimum	30 days
Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price	100%
Senior Notes | 2025 Notes | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Carrying amount										41,300,000
Senior Notes | 2025 Notes | Class A Common Stock
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 71,800,000
Debt issuance costs	$ 2,500,000
Senior Notes | 2025 Notes | Class A Common Stock | Common Class A
Debt Instrument [Line Items]
Initial conversion rate	0.0299135
Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt
Debt Instrument [Line Items]
Stockholders' equity										(71,800,000)
Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06 | Deferred Financing Fees
Debt Instrument [Line Items]
Stockholders' equity										2,500,000
Senior Notes | 2025 Notes | Retained Earnings (Accumulated Deficit) | Cumulative-effect adjustment from adoption of ASC 2020-06 | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity										$ 28,100,000

Long-term Debt - Convertible Se

Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Aug. 31, 2020	Oct. 31, 2018	Oct. 24, 2018	Oct. 22, 2018
2024 Notes
Debt Instrument [Line Items]
Carrying value	$ 24,018,000	$ 23,925,000
Unamortized debt discount and issuance costs	263,000	356,000
Principal amount	$ 24,281,000	$ 24,281,000	$ 117,100,000
Remaining amortization period (years)	1 year 4 months 24 days	1 year 10 months 24 days
2024 Notes | Level 2
Debt Instrument [Line Items]
Fair value	$ 38,000,000	$ 38,000,000
2025 Notes
Debt Instrument [Line Items]
Carrying value	169,527,000	168,885,000
Unamortized debt discount and issuance costs	2,973,000	3,615,000
Principal amount	$ 172,500,000	$ 172,500,000		$ 172,500,000	$ 22,500,000	$ 150,000,000
Remaining amortization period (years)	2 years 3 months 18 days	2 years 9 months 18 days
2025 Notes | Level 2
Debt Instrument [Line Items]
Fair value	$ 192,445,000	$ 185,546,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) customer	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Restricted Cash and Cash Equivalents Items [Line Items]
Automatic extension period			1 year
Automatic extension after each period			1 year
Percent of tax savings to be paid	85%		85%
Recognition of remaining TRA liability	$ 0	$ 0	$ 66,184	$ 0
Tax receivable agreement liability	112,134		$ 112,134		$ 45,950
UPMC Reseller Agreement
Restricted Cash and Cash Equivalents Items [Line Items]
Number of customers | customer			20
Letter of Credit | Line of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Maximum borrowing capacity	18,200		$ 18,200		13,100
Letter of Credit | Line of Credit | Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments	$ 18,200		$ 18,200		$ 13,100

Commitments and Contingencies_2

Commitments and Contingencies - Credit and Concentration Risk (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Percentage of cash and cash equivalents held with FDIC participating bank	99.20%		99.20%
Cash and cash equivalents (including restricted cash)	$ 207,599	$ 280,433	$ 207,599	$ 280,433	$ 215,158	$ 354,942
Percentage of cash held in international banks	0.80%		0.80%
Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (in percent)			35.40%		42.50%
Cook County Health and Hospitals System | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)	17.60%	24.10%	17.40%	24%
Centene Corporation | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)	10.30%
Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)	11.10%	11.70%	11.50%	11.80%
Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (in percent)			20.20%		12%
Molina Healthcare | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)	16.40%		14.90%
Bright Health Management, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (in percent)					11.30%
Blue Cross and Blue Shield of North Carolina | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)		10.20%

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) option_to_renew_lease	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Number of leases option | option_to_renew_lease			1
Right-of-use assets impairment	$ 24,065	$ 0	$ 24,065	$ 0
Lease Agreements
Lessee, Lease, Description [Line Items]
Letters of credit outstanding, amount	2,100		2,100
Restricted cash and restricted investments	$ 2,100		$ 2,100		$ 2,300

Leases - Primary Office Leases

Leases - Primary Office Leases (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Future Minimum Lease Commitments	$ 79,835
Arlington, VA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	8 years 7 months 6 days
Future Minimum Lease Commitments	$ 28,960
Letter of Credit Amount Required	$ 1,579
Edison, NJ
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	2 years 9 months 18 days
Future Minimum Lease Commitments	$ 1,495
Letter of Credit Amount Required	$ 222
Makati City, Philippines
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	4 years 10 months 24 days
Future Minimum Lease Commitments	$ 3,397
Letter of Credit Amount Required	$ 0
Alpharetta, GA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	2 years 3 months 18 days
Future Minimum Lease Commitments	$ 1,066
Letter of Credit Amount Required	$ 0
Pune, India
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	4 years 9 months 18 days
Future Minimum Lease Commitments	$ 2,765
Letter of Credit Amount Required	$ 0
Brea, CA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	3 years 10 months 24 days
Future Minimum Lease Commitments	$ 3,777
Letter of Credit Amount Required	$ 0

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Operating lease cost	$ (1,727)	$ 2,231	$ 213	$ 4,505
Variable lease cost	1,565	1,171	3,121	2,497
Total lease cost	$ (162)	$ 3,402	$ 3,334	$ 7,002

Leases - Maturity of Lease Liab

Leases - Maturity of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Leases [Abstract]
2023	$ 4,444
2024	11,610
2025	11,285
2026	10,291
2027	10,044
Thereafter	32,161
Total lease payments	79,835
Less:
Interest	17,041
Present value of lease liabilities	$ 62,794

Leases - Weighted-average Disco

Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)	Jun. 30, 2023
Leases [Abstract]
Weighted average discount rate	6.71%
Weighted average remaining lease term	7 years 6 months

Convertible Preferred Equity (D

Convertible Preferred Equity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended	6 Months Ended
	Jan. 20, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Temporary Equity [Line Items]
Aggregate shares of preferred stock sold (in shares)			175
Preferred class A common stock, par value (in dollars per share)		$ 0.01	$ 0.01		$ 0.01
Class A common stock, par value (in dollars per share)		$ 0.01	$ 0.01		$ 0.01
Payment of preferred dividends			$ 8,535	$ 0
Series A Preferred Stock
Temporary Equity [Line Items]
Aggregate shares of preferred stock sold (in shares)	175
Preferred class A common stock, par value (in dollars per share)	$ 0.01
Purchase price (in dollars per share)	$ 960
Gross proceeds from sale of temporary equity	$ 168,000
Liquidation preference (in dollars per share)	$ 1,000
Annual increase in dividend rate	2%
Conversion price (in dollar per share)	$ 40
Payment of preferred dividends		$ 4,900	$ 8,500
Dividends paid (in dollars per share)		$ 27.91	$ 48.77
Accretion of Series A preferred stock		$ 2,200	$ 4,800
Series A Preferred Stock | Called by company on or after January 20, 2025
Temporary Equity [Line Items]
Redemption price percentage	165%
Series A Preferred Stock | Called by holder on or after January 20, 2030
Temporary Equity [Line Items]
Redemption price percentage	150%
Series A Preferred Stock | Refinancing or replacement of debt
Temporary Equity [Line Items]
Redemption price percentage	165%
Series A Preferred Stock | Change of control prior to January 20, 2025
Temporary Equity [Line Items]
Redemption price percentage	150%
Series A Preferred Stock | Change of control after January 20, 2025
Temporary Equity [Line Items]
Redemption price percentage	135%
Series A Preferred Stock | Secured Overnight Financing Rate (SOFR)
Temporary Equity [Line Items]
Quarterly dividend rate, basis spread on variable rate	6%
Common Class A
Temporary Equity [Line Items]
Class A common stock, par value (in dollars per share)	$ 0.01

Loss Per Common Share - Computa

Loss Per Common Share - Computation of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss attributable to common shareholders of Evolent Health, Inc - Basic	$ (41,411)	$ (4,588)	$ (67,669)	$ (9,938)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted	$ (41,411)	$ (4,588)	$ (67,669)	$ (9,938)
Weighted-average common shares outstanding - basic (in shares)	111,278	90,071	109,540	89,792
Weighted-average common shares outstanding - diluted (in shares)	111,278	90,071	109,540	89,792
Loss per common share
Basic (in dollars per share)	$ (0.37)	$ (0.05)	$ (0.62)	$ (0.11)
Diluted (in dollars per share)	$ (0.37)	$ (0.05)	$ (0.62)	$ (0.11)

Loss Per Common Share - Antidil

Loss Per Common Share - Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	12,612	15,076	13,174	15,206
Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs")
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,073	1,642	1,505	1,817
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	976	1,852	1,106	1,807
Series A Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,375	0	4,375	0
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,188	11,582	6,188	11,582

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total compensation expense by financial statement line item	$ 8,966	$ 7,012	$ 19,676	$ 12,358
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total compensation expense by financial statement line item	42	1,162	1,582	1,962
Selling, general and administrative expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total compensation expense by financial statement line item	8,924	5,850	18,094	10,396
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total compensation expense by financial statement line item	14	91	74	253
RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total compensation expense by financial statement line item	6,903	4,647	14,392	7,948
LSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total compensation expense by financial statement line item	77	382	361	1,157
PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total compensation expense by financial statement line item	$ 1,972	$ 1,892	$ 4,849	$ 3,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based compensation capitalized	$ 0	$ 0	$ 0	$ 0

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Stock-Based Awards Granted (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	57	63	1,053	980
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	8	0	432	479

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ (970)	$ (184)	$ (69,159)	$ 1,018
Effective tax rate	2.70%	3.90%	56%	(11.40%)
Reduction of valuation allowance			$ 56,100
Unrecognized tax benefits	$ 1,600		$ 1,600
Amount of tax benefit percent			85%

Investments in Equity Method _2

Investments in Equity Method Investees (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Gain from equity method investees	$ 155	$ 1,952	$ 578	$ 2,548
Equity Method Investee | Services Agreements
Schedule of Equity Method Investments [Line Items]
Revenue related to services agreements	$ 4,600	$ 3,900	$ 9,400	$ 7,500
Minimum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	4%		4%		4%
Voting interest percentage	25%		25%		25%
Maximum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	38%		38%		38%
Voting interest percentage	40%		40%		40%

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Liabilities
Contingent consideration	$ 113,300	$ 78,000
Total fair value of liabilities measured on a recurring basis	113,300	78,000
Level 1
Liabilities
Contingent consideration	0	0
Total fair value of liabilities measured on a recurring basis	0	0
Level 2
Liabilities
Contingent consideration	0	0
Total fair value of liabilities measured on a recurring basis	0	0
Level 3
Liabilities
Contingent consideration	113,300	78,000
Total fair value of liabilities measured on a recurring basis	$ 113,300	$ 78,000

Fair Value Measurement - Change

Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance as of beginning of period	$ 78,000	$ 28,700
Additions	66,600	0
Settlements	$ (32,047)	$ 0
Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag	Total (gain) loss, net	Total (gain) loss, net
Total (gain) loss, net	$ 747	$ 4,700
Balance as of end of period	$ 113,300	$ 33,400

Fair Value Measurement - Valuat

Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring $ in Thousands	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 113,300	$ 78,000
Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 113,300	$ 78,000
Level 3 | Risk-neutral expected earnout consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or input ranges	113,300	77,946
Level 3 | Discount rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or input ranges	0.0850	0.0985
Level 3 | Discount rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or input ranges	0.1398	0.1001

Related Parties - Assets and Li

Related Parties - Assets and Liabilities (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Assets
Accounts receivable, net	[1]	$ 345,276	$ 254,684
Prepaid expenses and other current assets	[1]	41,416	20,678
Liabilities
Accounts payable	[1]	76,953	57,174
Accrued liabilities	[1]	166,676	111,198
Related Party
Assets
Accounts receivable, net		7,326	8,787
Prepaid expenses and other current assets		43	0
Liabilities
Accounts payable		0	27
Accrued liabilities		$ 0	$ 192
[1]See Note 18 for amounts attributable to related parties included in these line items.

Related Parties - Revenues and

Related Parties - Revenues and Expenses (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Expenses
Selling, general and administrative expenses	[1]	$ 90,389	$ 58,955	$ 180,115	$ 117,887
Related Party
Related Party Transaction [Line Items]
Revenue		39,486	42,810	94,207	74,874
Expenses
Cost of revenue		32,076	36,684	79,582	63,145
Selling, general and administrative expenses		$ 997	$ 236	$ 1,239	$ 302
[1]See Note 18 for amounts attributable to unconsolidated related parties included in these line items.

Repositioning and Other Chang_3

Repositioning and Other Changes (Details) - Repositioning Plan $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Expected cost of restructuring	$ 25,325	$ 25,325
Restructuring charges	11,261	11,261
Severance and termination benefits
Restructuring Cost and Reserve [Line Items]
Expected cost of restructuring	7,300	7,300
Restructuring charges	4,737	4,737
Dedicated employee costs
Restructuring Cost and Reserve [Line Items]
Expected cost of restructuring	7,725	7,725
Restructuring charges	1,737	1,737
Professional services
Restructuring Cost and Reserve [Line Items]
Expected cost of restructuring	10,300	10,300
Restructuring charges	$ 4,787	$ 4,787

Reserves for Claims and Perfo_3

Reserves for Claims and Performance-Based Arrangements (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	$ 199,730	$ 171,294
Incurred health care costs:
Current year to date period	385,459	246,955
Prior year to date period	(26,474)	22,438
Total claims incurred	358,985	269,393
Claims paid related to:
Current year to date period	(179,472)	(201,508)
Prior year to date period	(133,432)	(101,145)
Total claims paid	(312,904)	(302,653)
Other adjustments	0	(12,074)
Balance, end of period	$ 245,811	$ 125,960

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Supplemental Disclosure of Non-cash Investing and Financing Activities
Accrued property and equipment purchases	$ 24	$ 1,118
Increase/decrease to goodwill from measurement period adjustments/business combinations	(391)	0
Class A common stock issued in connection with business combinations	261,271	0
Effects of Leases
Operating cash flows from operating leases	6,532	7,010
Leased assets disposed of (obtained in) exchange for operating lease liabilities	$ 1,941	$ 4,153

Subsequent Events (Details)

Subsequent Events (Details) - 2024 Notes $ / shares in Units, $ in Thousands	Aug. 02, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Aug. 31, 2020 USD ($) $ / shares
Convertible senior notes | Subsequent event
Subsequent Event [Line Items]
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100%
Conversion price (in dollars per share) | $ / shares	$ 0.01
Initial conversion rate	0.0548557
Senior Notes
Subsequent Event [Line Items]
Interest rate				3.50%
Conversion price (in dollars per share) | $ / shares				$ 18.23
Principal amount | $		$ 24,281	$ 24,281	$ 117,100
Senior Notes | Subsequent event
Subsequent Event [Line Items]
Principal amount | $	$ 24,300

Uncategorized Items - evh-20230

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2020-06 [Member]